US20200031893A1 - Novel prongf mutants and uses thereof in the production of beta-ngf - Google Patents
Novel prongf mutants and uses thereof in the production of beta-ngf Download PDFInfo
- Publication number
- US20200031893A1 US20200031893A1 US16/376,969 US201916376969A US2020031893A1 US 20200031893 A1 US20200031893 A1 US 20200031893A1 US 201916376969 A US201916376969 A US 201916376969A US 2020031893 A1 US2020031893 A1 US 2020031893A1
- Authority
- US
- United States
- Prior art keywords
- ngf
- prongf
- beta
- biologically active
- mutant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 24
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 102
- 230000007017 scission Effects 0.000 claims abstract description 102
- 108091005804 Peptidases Proteins 0.000 claims abstract description 64
- 239000004365 Protease Substances 0.000 claims abstract description 64
- 238000000034 method Methods 0.000 claims abstract description 56
- 101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 claims abstract description 51
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract 8
- 229940024606 amino acid Drugs 0.000 claims description 97
- 235000001014 amino acid Nutrition 0.000 claims description 97
- 150000001413 amino acids Chemical class 0.000 claims description 94
- 239000000243 solution Substances 0.000 claims description 44
- 102000004142 Trypsin Human genes 0.000 claims description 42
- 108090000631 Trypsin Proteins 0.000 claims description 42
- 239000012588 trypsin Substances 0.000 claims description 36
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 34
- 239000004475 Arginine Substances 0.000 claims description 30
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 30
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 30
- 210000003000 inclusion body Anatomy 0.000 claims description 25
- 239000004472 Lysine Substances 0.000 claims description 21
- 239000000872 buffer Substances 0.000 claims description 20
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 17
- VBAOEVKQBLGWTH-UHFFFAOYSA-N 2-pyridin-4-ylethanethiol Chemical compound SCCC1=CC=NC=C1 VBAOEVKQBLGWTH-UHFFFAOYSA-N 0.000 claims description 15
- 229960003180 glutathione Drugs 0.000 claims description 15
- 235000018417 cysteine Nutrition 0.000 claims description 14
- 102100023995 Beta-nerve growth factor Human genes 0.000 claims description 13
- 101710129634 Beta-nerve growth factor Proteins 0.000 claims description 13
- 230000003196 chaotropic effect Effects 0.000 claims description 13
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 12
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 11
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 11
- 239000012535 impurity Substances 0.000 claims description 11
- 238000005063 solubilization Methods 0.000 claims description 11
- 230000007928 solubilization Effects 0.000 claims description 11
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 10
- 239000003446 ligand Substances 0.000 claims description 10
- 239000002738 chelating agent Substances 0.000 claims description 8
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 claims description 8
- 108010024636 Glutathione Proteins 0.000 claims description 7
- 108010053070 Glutathione Disulfide Proteins 0.000 claims description 7
- 239000006227 byproduct Substances 0.000 claims description 7
- 239000003638 chemical reducing agent Substances 0.000 claims description 7
- 230000003297 denaturating effect Effects 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 238000004587 chromatography analysis Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 102000012479 Serine Proteases Human genes 0.000 claims description 5
- 108010022999 Serine Proteases Proteins 0.000 claims description 5
- 239000007983 Tris buffer Substances 0.000 claims description 5
- 238000004153 renaturation Methods 0.000 claims description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 5
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 4
- 108010006519 Molecular Chaperones Proteins 0.000 claims description 4
- 229960003067 cystine Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 239000004158 L-cystine Substances 0.000 claims description 3
- 235000019393 L-cystine Nutrition 0.000 claims description 3
- 125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 3
- 125000006247 phenyl propyl amino group Chemical group [H]N(*)C([H])([H])C([H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- WOUANPHGFPAJCA-UHFFFAOYSA-N 2-[benzyl(methyl)amino]ethanol Chemical compound OCCN(C)CC1=CC=CC=C1 WOUANPHGFPAJCA-UHFFFAOYSA-N 0.000 claims description 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 238000012434 mixed-mode chromatography Methods 0.000 claims description 2
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 claims description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 76
- 102000004169 proteins and genes Human genes 0.000 description 62
- 235000018102 proteins Nutrition 0.000 description 58
- 102000035195 Peptidases Human genes 0.000 description 56
- 108010025020 Nerve Growth Factor Proteins 0.000 description 44
- 102000015336 Nerve Growth Factor Human genes 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 34
- 239000000047 product Substances 0.000 description 21
- 238000000746 purification Methods 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 17
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 14
- 238000006467 substitution reaction Methods 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- 230000029087 digestion Effects 0.000 description 12
- 102000014193 human pro-nerve growth factor Human genes 0.000 description 11
- 108010011947 human pro-nerve growth factor Proteins 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 229960002433 cysteine Drugs 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 9
- 238000010828 elution Methods 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 8
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 8
- 229920002684 Sepharose Polymers 0.000 description 8
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 7
- 229960003767 alanine Drugs 0.000 description 7
- 235000004279 alanine Nutrition 0.000 description 7
- 238000004925 denaturation Methods 0.000 description 7
- 230000036425 denaturation Effects 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 229960001153 serine Drugs 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004961 Furin Human genes 0.000 description 6
- 108090001126 Furin Proteins 0.000 description 6
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 6
- 238000004220 aggregation Methods 0.000 description 6
- 239000003599 detergent Substances 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 101001051709 Homo sapiens Ribosomal protein S6 kinase-related protein Proteins 0.000 description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- 102100024914 Ribosomal protein S6 kinase-related protein Human genes 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 210000001236 prokaryotic cell Anatomy 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 4
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000000172 cytosol Anatomy 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 235000003969 glutathione Nutrition 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 239000011537 solubilization buffer Substances 0.000 description 4
- 229960004295 valine Drugs 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001945 cysteines Chemical class 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 238000011194 good manufacturing practice Methods 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 229960003136 leucine Drugs 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 229960005190 phenylalanine Drugs 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229960002429 proline Drugs 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229960004799 tryptophan Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 102100027612 Kallikrein-11 Human genes 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- -1 Lysine (Lys Chemical class 0.000 description 2
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 101710152431 Trypsin-like protease Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000013019 capto adhere Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000002932 cholinergic neuron Anatomy 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000013578 denaturing buffer Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 230000001810 trypsinlike Effects 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102220469899 CTP synthase 1_K103Q_mutation Human genes 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical class NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
- 241000677647 Proba Species 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 102000003667 Serine Endopeptidases Human genes 0.000 description 1
- 108090000083 Serine Endopeptidases Proteins 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241001672648 Vieira Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 230000006328 chemical modification of amino acids Effects 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011118 depth filtration Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 229940045883 glutathione disulfide Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 101150070420 gyrA gene Proteins 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 102000046917 human NGF Human genes 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 239000013315 hypercross-linked polymer Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 101150011498 lad gene Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108010071286 prethrombins Proteins 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to novel proNGF mutants having substitutions at the native protease cleavage site.
- the present invention further discloses a method of producing a biologically active human beta-NGF from an inactive insoluble proNGF mutant and the use of a proNGF mutant for producing human beta-NGF.
- Beta-NGF Nerve growth factor
- Possible therapeutic indications for recombinant human nerve growth factor include peripheral sensory neuropathies, e.g. associated with diabetes or as a possible side effect in AIDS therapy.
- Other indications for beta-NGF are central neuropathies, e.g. Alzheimer's disease. In this case, the loss of memory is the result of a loss of cholinergic neurons.
- Beta-NGF has also been found to be effective in the treatment of human cutaneous and corneal ulcers (Beniabei et al. Lancet 1999; Lambiase et al. NEJM 1998). Moreover.
- Beta-NGF has also been shown to protect retinal cells from degeneration and apoptosis in an experimental animal model of glaucoma and to improve visual function in a few patients affected by glaucoma (Lambiase A, et al. PNAS 2009).
- Mature human beta-NGF is a 118 amino acid protein which is translated as a preproprotein consisting of 241 amino acids.
- the signal peptide (prepeptide) of 18 amino acids is cleaved during translocation into the endoplasmic reticulum (ER).
- the resulting proprotein (proNGF) is processed at its N-terminus by removing the pro-sequence by protease cleavage.
- Mature human NGF shows a high degree of identity (about 90%) to rodent (murine and rat) beta-NGF.
- beta-NGF has to be provided in high concentrations.
- Submaxillary glands of mice are a natural source of beta-NGF.
- these beta-NGF preparations are heterogeneous mixtures of different dimers and thus not suitable for therapeutic uses.
- the prosequence is a domain separate from the mature protein (see the sequence data in FIG. 1 , wherein the prosequence is indicated in bold). These two domains are separated by an exposed protease cleavage site with a basic amino acid target sequence of the type Arg-Ser-Lys-Arg located at positions 101 to 104 of the human proNGF sequence (SEQ ID NO: 1). This motif is naturally a cleavage site for the serine endoprotease Furin. Additionally, the cleavage site may be specifically processed by other suitable proteases, preferably by proteases with substrate specificity of cleavage after the amino acid Arginine (Arg, R). For example, the protease trypsin cleaves after basic amino acids such as Lysine (Lys, K) or Arginine (Arg, R).
- beta-NGF is obtainable from recombinant insoluble inactive proNGF which solubilized in a denaturing solution. Afterwards, the solubilized proNGF is transferred into a non- or weakly denaturing solution. The denatured proNGF assumes a biologically active conformation as determined by the disulfide bonds present in native beta-NGF. Subsequently, the prosequence of proNGF is cleaved off whereby active beta-NGF is obtained.
- Human proNGF contains a native protease (Furin) cleavage site Arg-Ser-Lys-Arg, thus having the following sequence motif: R 1 SK 3 R 4 .
- Furin native protease
- Arg-Ser-Lys-Arg a native protease (Furin) cleavage site Arg-Ser-Lys-Arg
- R 1 SK 3 R 4 a native protease
- materials such as enzymes have to be provided in high quality.
- the protease Furin is currently not available as GMP-grade protease.
- Trypsin (EC 3.4.21.4) was chosen to cleave proNGF to result in a mature beta-NGF protein.
- the serine protease Trypsin cleaves peptide chains at the carboxyl side of basic amino acids Arginine or Lysine.
- the naturally occuring cleavage site in human proNGF contains three positions with basic amino acids (positions 101, 103, and 104 of SEQ ID NO: 1; alternatively referred to as R 1 , K 3 and R 4 herein).
- R 1 , K 3 and R 4 alternative protease
- Typical cleavage products are SK 3 R 4 -beta-NGF and R 4 -beta-NGF and mature beta-NGF. This problem is exacerbated since dimerization of the beta-NGF protein will lead to an even higher number (up to six) of inhomogenous products which have to be purified in following steps (see FIG. 2 a ).
- betaNGF Methods for producing betaNGF have been described in the prior art. However, the currently available production processes have several drawbacks, such as inhomogenous beta-NGF products and low yields of beta-NGF.
- An advantage of the invention is the production of a beta-NGF from a novel proNGF mutant.
- the novel mutant results in homogenous beta-NGF products in good yield because the novel proNGF mutant prevents inhomogeneous digestion by proteases and thus inhomogenous beta-NGF products.
- the problem of the invention is solved by providing the proNGF mutant of the invention and the method of producing beta-NGF from the proNGF mutant as described by the present invention.
- novel mutant results in an unexpected and striking increase in the efficiency of the cleavage of trypsin at the relevant site in the mutated proNGF of the invention compared to the wild type. This allows to use extremely low amounts of the protease trypsin as compared to the amount to be used on the wild type and, as a consequence, results in reduced problems of purification of beta NGF from the enzyme itself and from by products of the cleavage.
- the present invention relates to a proNGF mutant, wherein the protease cleavage site R 1 SK 3 R 4 is substituted at least at positions R 1 and K 3 corresponding to positions 101 and 103 of the human wildtype proNGF sequence (SEQ ID NO: 1) by an amino acid selected from non-basic amino acids and Histidine.
- the present invention relates to a method of preparing a biologically active human beta-NGF from an inactive insoluble proNGF mutant substituted at the native protease cleavage site R 1 SK 3 R 4 at least at positions R 1 and K 3 corresponding to positions 101 and 103 of the human wildtype proNGF sequence (SEQ ID NO: 1), comprising (i) providing a proNGF mutant according to this invention, and (ii) cleaving the proNGF mutant in order to obtain active human beta-NGF.
- the invention relates to the following process:
- a third aspect of the invention relates to the use of a proNGF mutant wherein at least Arginine at position 101 and the Lysine at position 103 of the native protease cleavage site R 1 SK 3 R 4 at positions 101 to 104 of the human wildtype proNGF (SEQ ID NO: 1) is substituted by non-basic amino acids for the preparation of human beta-NGF.
- a further aspect of the present invention relates to pharmaceutical compositions comprising beta-NGF produced from the proNGF mutant wherein at least Arginine at position 101 and Lysine at position 103 of the native protease cleavage site R 1 SK 3 R 4 at positions 101 to 104 of the human wildtype proNGF (SEQ ID NO: 1) are substituted by an amino acid selected from non-basic amino acids and Histidine and a pharmaceutically acceptable carrier or diluent.
- proNGF or “pro-NGF” refers to the pro-form of human beta-NGF.
- the full human proNGF sequence is defined in SEQ ID NO: 1 ( FIG. 1 a ).
- the prosequence of beta-NGF is a domain separate from the mature beta-NGF. Between these two domains, there is a native protease cleavage site Arg-Ser-Lys-Arg (referred herein to R 1 SK 3 R 4 , SEQ ID NO: 9) at positions 101 to 104 of SEQ ID NO: 1.
- the cleavage site may be specifically processed by suitable proteases, in particular furin protease.
- proNGF mutant or “proNGF mutein” refers to modifications of the pro-form of human beta-NGF by substitutions of amino acids.
- the proNGF mutein of the present invention is substituted at the native protease cleavage site R 1 SK 3 R 4 (SEQ ID NO: 9) at least at both positions K 3 and R 1 corresponding to positions 101 and 103 of the human wild type proNGF sequence (SEQ ID NO: 1) by an amino acid selected from non-basic amino acids and Histidine.
- amino acid Lysine in Position K 3 (corresponding to position 103) is substituted with Alanine (see FIG. 1 d, SEQ ID NO: 4, FIG. 1 e, SEQ ID NO: 5, FIG. 1 g , SEQ ID NO: 8).
- amino acid Arginine in position R 1 (corresponding to position 101) is substituted with Valine (see FIG. 1 b, SEQ ID NO: 2, FIG. 1 e, SEQ ID NO: 5, FIG. 1 g, SEQ ID NO: 8).
- the amino acid arginine R 4 corresponding to position 104 of the wildtype proNGF sequence may also be substituted by any amino acid which allows processing of the proNGF by proteolytic cleavage to obtain beta NGF, preferably a basic amino acid such as Arginine or Lysine.
- a basic amino acid such as Arginine or Lysine.
- Protease cleavage sites of pro NGF and proNGF muteins (X refers to any amino acid but not Arg or Lys)
- Protease cleavage site SEQ ID NO: (pos. 101-104 of SEQ ID NO: 1) 1 RSKR (wild-type) 2 VSXR 3 XSXR 4 XSAR 5 VSAR 6 XXXR 7 VXAR
- non-basic amino acid refers to any amino acid which is not positively charged.
- the term refers to an amino acid residue other than a basic amino acid.
- the term excludes amino acids Lysine or Arginine which are amino acids with positive side chains.
- Non-basic amino acids are negatively charged amino acids Glutamic Acid and Aspartic Acid, amino acids with polar uncharged side chains (Serine, Threonine, Asparagine, Glutamine), amino acids with hydrophobic side chains (Alanine, Valine, Isoleucine, Leucine, Methionine, Phenylalanine, Tyrosine, Tryptophane) and amino acids Cysteine, Glycine and Proline.
- biologically active pro-NGF or “proNGF with biologically active conformation” as such refers to the biological activity of pro-NGF.
- a biologically active conformation of proNGF is determined by the presence of disulfide bridges occurring in natural beta-NGF. The activity may be, for example, determined according to an assay as described by Chevalier et al. 1994, Blood 83: 1479-1485, 1994, which is incorporated herein by reference.
- Example 11 describes an assay for the biological activity of proNGF via stimulation of the proliferation of TF1 cells.
- beta-NGF refers to a mature beta-nerve growth factor, preferably from human.
- the sequence for the mature beta-nerve growth factor is shown in FIG. 1 (SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, SEQ ID NO: 7, and SEQ ID NO: 8), starting at position 105.
- beta-NGF activity of beta-NGF or “biologically active beta-NGF” as such means the biological activity of beta-NGF.
- Biologically active beta-NGF exists in the form of a dimer.
- Beta-NGF must be present in a dimeric form to have a biologically active conformation.
- the prerequisite of a biologically active conformation of beta-NGF is the correct formation of the disulfide bridges to a cystine knot.
- the activity may be, for example, determined according to the DRG assay (dorsal root ganglion assay), see for example Levi-Montalcini, R. et al., Cancer Res. 14 (1954) 49, and Varon, S. et al., Meth. in Neurochemistry 3 (1972) 203. In this assay the stimulation and survival of sensory neurons from dissociated dorsal root ganglia of chick embryos is monitored by means of neurite formation.
- substitution refers to modifications of the pro-form of human beta-NGF by replacement of amino acids.
- the term comprises the chemical modification of amino acids by e.g. substituting or adding chemical groups or residues to the original amino acid.
- the step of modification of the selected amino acids is performed preferably by mutagenesis on the genetic level.
- the modification of proNGF is carried out by means of methods of genetic engineering for the alteration of a DNA belonging to proNGF.
- the modifications are mutations that cause the replacement of a single base nucleotide with another nucleotide of the genetic material. Point mutations results in encoding different amino acids compared to the wild-type sequence.
- expression of the modified proNGF protein is then carried out in prokaryotic or eukaryotic organisms, most preferably in prokaryotic organisms.
- the term “denaturating” or “denaturation” refers to a process in which the folding structure of a protein is altered.
- the term refers to unfold the tertiary structure of proNGF or proNGF mutein.
- the alteration of the folding structure is due to exposure to certain chemical or physical factors. As a result, some of the original properties of the protein, especially its biological activity, are diminished or eliminated. Due to the denaturing process, proteins become biologically inactive. Further, denatured proteins can exhibit a wide range of characteristics, including loss of biological function, loss of solubility and/or aggregation.
- refolding or “renaturating” or “renaturation” refers to a process by which the protein structure assumes its native functional fold or conformation. Due to renaturation or refolding processes, the protein becomes biologically active.
- the term “recombinant” refers to the cloning of DNA into vectors for the expression of the protein encoded by the DNA in a suitable host.
- the host is preferably a prokaryote, most preferably a bacterium.
- a “recombinant expression” as used herein refers to expression of proNGF or the proNGF mutein in in prokaryotic host cells, for example E. coli strains suitable for expression of recombinant proteins could be used.
- soluble refers to a protein which is susceptible of being dissolved in some solvent.
- insoluble refers to a protein which is not susceptible of being dissolved in some solvent.
- the present invention provides a proNGF mutant wherein the protease cleavage site R 1 SK 3 R 4 is substituted at least at positions R 1 and K 3 corresponding to positions 101 and 103 of the human wildtype proNGF sequence (SEQ ID NO: 1) by an amino acid selected from non-basic amino acids and Histidine.
- the protease cleavage site R 1 SK 3 R 4 is substituted at least at positions R 1 and K 3 corresponding to positions 101 and 103 of the human wildtype proNGF sequence (SEQ ID NO: 1) by an amino acid selected from non-basic amino acids and Histidine.
- at least Arginine R 1 at position 101 and the Lysine K 3 at position 103 of the native protease cleavage site R 1 SK 3 R 4 at positions 101 to 104 of the human wild type proNGF sequence (SEQ ID NO: 1) are substituted by any amino acid but not Arginine or Lysine.
- the native protease cleavage side refers to amino acids positions 101 to 104 (ArgSerLysArg, RSKR, SEQ ID NO: 9).
- Amino acid Lysine K 3 in position 103 of the wild-type proNGF sequence and amino acid Arginine R 1 in position 101 are replaced with any amino acid but not Arg or Lys to result in a proNGF with improved properties in particular for producing beta-NGF.
- Arginine (R 1 ) or Lysine (K 3 ) may be substituted by all naturally occurring amino acids, or artificial amino acids as well, provided they do not constitute a cleavage site for trypsin.
- the amino acid modifications to one or more positions corresponding to residues 101-103 may be substitutions that replace basic amino acids with non-basic amino acids. Theses substitutions can be used to create proNGF mutants according to the invention, in particular, for the production of beta-NGF.
- Mutants comprise substitutions at least at positions Arg101 and Lys103. The amino acid residues are replaced by a non-basic amino acid or Histidine. Particularly, the mutants of the invention have the substitutions Arg101Val and Lys103Ala.
- said natural non-basic amino acids may be selected from the group consisting of the naturally occurring amino acid residues Alanine, Asparagine, Aspartic Acid, Cysteine, Glutamine, Glutamic Acid, Glycine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serine, Threonine, Tryptophan, Tyrosine, Valine.
- Amino acids for substitutions at positions 101 and 103 are not selected from basic (positively charged) amino acids Arginine (Arg) and Lysine (Lys). Also less preferred are amino acids Isoleucine (Ile), Leucine (Leu), or Phenylalanine (Phe), Cysteine (Cys), Proline (Pro) or Tryptophan (Trp). Serine (Ser) is naturally occurring in position 102 of the human proNGF wild-type sequence.
- X in position 102 is preferably selected from Serine (Ser) which is naturally occurring in position 102 of the human proNGF sequence, but may also be selected from any other amino acid wherein the amino acid must be a non-basic amino acid (i.e. not Arginine or Lysine). It is important that the amino acid in position 102 is a non-basic amino acid (i.e. not Arg or Lys).
- the amino acid in position 104 of the wild-type human proNGF sequence is preferably Arginine (Arg) which is naturally occurring in position 104 of the human proNGF sequence, but may also be substituted by any other amino acid, preferably a basic amino acid, more preferably Lysine, which allows processing of the proNGF by proteolytic cleavage to obtain beta NGF.
- Arg Arginine
- Table 2 summarizes the preferred substitutions for the protease cleavage site of proNGF.
- Table 2A Preferred amino acids in positions 101-104 of wild-type proNGF
- the star (*) shows the naturally occurring amino acid in the protease cleavage site (wild-type proNGF, SEQ ID NO: 1). 101 Val, Ala, Asn, Asp, Glu, Gln, Gly, Ser, Thr, Tyr, Met, His, Cys, Pro, Phe, Trp, Ile, Leu 102 Ser*, Gly, Asp, Tyr, Thr, Asn, Glu, Ala, Val, Gln, His, Met, Cys, Pro, Phe, Trp, Ile, Leu 103 Ala, Val, Asp, Asn, Glu, Gln, Gly, Ser, Thr, Tyr, Met, His, Cys, Pro, Phe, Trp, Ile, Leu 104 Arg*, Lys Amino acids Cys, Pro, Phe, Trp, Ile and Leu are less preferred substitutions at Positions 101, 102, and 103.
- the preferred substituted amino acid in position 101 of human wild-type proNGF is Valine
- in position 103 of human wild-type proNGF is Alanine
- in position 102 of human wild-type proNGF Serine in position 104 of human wild-type proNGF Arginine.
- the proNGF mutant of the invention presents has a sequence corresponding to that of SEQ ID NO: 5.
- the present invention is also directed to nucleic acids coding for the proNGF mutants described herein as well.
- the present invention is directed to a method of preparing a biologically active human beta-NGF from an inactive insoluble proNGF mutant substituted at the native protease cleavage site R 1 SK 3 R 4 (SEQ ID NO: 9) at positions 101 and 103 (R 1 and K 3 ) of the human wildtype proNGF sequence (SEQ ID NO: 1), comprising providing a proNGF mutant substituted at the native protease cleavage site R 1 SK 3 R 4 at positions 101 and 103 (R 1 and K 3 ) of the human wildtype proNGF sequence, and cleaving the proNGF mutant in order to obtain active human beta-NGF.
- the proNGF mutant is obtained by recombinant expression in prokaryotic cells.
- Suitable bacterial strains are well known in the art, e.g., E. coli, Bacillus sp., and Salmonella, and kits for such expression systems are commercially available.
- the preferred host cells for recombinant expression are E. coli, for example E. coli BL21, JM 108/109 (K12), JM106, JM83 and TB1 or derivatives thereof. Any other E. coli strain suitable for expression of recombinant proteins could be used.
- Polynucleotides are operatively linked to expression control sequences allowing expression of the fusion proteins of the invention in prokaryotic host cells.
- expression control sequences include but are not limited to inducible and non-inducible promoters, operators, repressors and other elements that are known to those skilled in the art and that drive or otherwise regulate gene expression.
- regulatory elements include as for example T7, TAC, PBAD, LAC promoters, Lad, LacI Q repressors.
- the sequence of the proNGF mutant is introduced into the prokaryotic host cell by a suitable vector.
- Suitable Vectors could be for example but not limited to: pBR322, pMAL, pUC19 and all derivatives.
- the prokaryotic host cell includes but is not limited to prokaryotic cells such as bacteria (for example, E. coli or B. subtilis ), which can be transformed with, for example, plasmid DNA, recombinant bacteriophage DNA, or cosmid DNA expression vectors containing the polynucleotide molecules of the invention.
- plasmid vectors are use.
- plasmid vectors described in EP1697523B1 may be used (which is incorporated by reference herein).
- an expression vector that contains
- proprietary expression vectors (Scil Proteins GmbH, see EP1697523B1 for the structure of a suitable expression vector) or commercially available vectors may be used for cloning.
- general information on the vectors which might be used in the method of the present invention it is referred to the above mentioned details.
- any suitable vectors might be used as known in the art.
- the method of the preparation of a proNGF mutant is comprising the following initial steps:
- the proNGF mutein Due to its expression in prokaryotic host cells, the proNGF mutein is in the form of its inactive, insoluble form.
- the method of production of beta-NGF from a proNGF mutant according to the present invention comprises the steps of:
- Step a) corresponds to dissolving the proNGF mutant substituted at the native protease cleavage site R 1 SK 3 R 4 at positions R 1 and K 3 corresponding to positons 101 and 103 of the human wildtype proNGF sequence (SEQ ID NO: 1) by solubilisation of inclusion bodies in a denaturating solution.
- the proNGF mutant of the invention in step a) usually is in the form of its inactive, insoluble form due to its expression in prokaryotic host cells. Inactive proNGF showing a poor solubility is formed during overexpression of the protein in the cytosol of prokaryotes. In this case, proNGF prepared by recombination remains in the cytoplasm in an insoluble and aggregated form.
- the prokaryotic cells are disrupted following fermentation.
- Cell disruption may be performed by conventional methods, e.g. by means of high pressure homogenization, sonification or lysozyme (Rudolph, R., et al. (1997); Folding proteins. In: Creighton, T. E. (ed.): Protein Function: A Practical Approach. Oxford University Press, pp. 57-99).
- inclusion bodies are solubilized.
- Inclusion bodies (TB) are accumulations of usually defective or incompletely folded proteins. They form inside cells, for example bacteria cells, such as E. coli, in the event of excessive expression of recombinant proteins.
- the inclusion bodies employed according to the invention preferably comprise the proNGF mutein. This means that they contain at least 60, at least 70, at least 80 or at least 90 wt. % of pro-NGF (based on the total amount of protein).
- the invention provides a method for the production of proNGF mutein thereof, wherein inclusion bodies which non-folded, inactive, insoluble proNGF mutein or a derivative thereof are solubilized in a denaturing buffer (solution).
- the denaturating solution of step a) preferably comprises a solution containing (i) a chaotropic agent, (ii) a chelator, (iii) a buffer, and (iv) a reducing agent.
- the denaturation buffer comprises at least one chaotropic substance (agent).
- Chemical substances which dissolve ordered hydrogen bridge bonds in water are called chaotropic. Since the hydrogen bridge bonds are broken open, the chaotropic substances interfere with the water structure and ensure disorder (increase in entropy). The reason for this is that the formation of the H 2 O cage structures necessary for the solvation is prevented.
- amino acids they reduce the hydrophobic effects and have a denaturing action on proteins, since a driving force of protein folding is the assembling together of hydrophobic amino acids in water.
- any substance which exerts the hydrophobic effect in the solubilization buffer and therefore has a denaturing action on the proteins can be employed as a chaotropic substance.
- Chaotropic substances are in general salts or low molecular weight compounds, such as urea. Chaotropic substances are clearly distinguished from detergents, since they contain no hydrophobic radical, such as an alkyl radical, in the molecule. Generally, the chaotropic action is accompanied by an improvement in the solubility of the protein, in this case the prethrombin.
- the chaotropic compound is chosen from guanidinium salts, in particular guanidinium hydrochloride and guanidinium thiocyanate, iodides, barium salts, thiocyanates, urea and perchlorates.
- the chaotropic compounds are employed in conventional amounts.
- 4-8 M guanidinium hydrochloride or 4-9 M urea can be employed.
- the denaturation buffer comprises a reducing agent compound, for example a disulphide compound such as Glutathione (GSH).
- the disulphide compound is capable of forming mixed disulphides with thiol groups (—SH) of cysteines of the polypeptides in the inclusion bodies.
- the disulphide is added to the solution.
- the disulphide does not designate proteins which the inclusion bodies comprise and which possibly comprise disulphide bridges.
- the disulphide is not a true peptide.
- the disulphide is a low molecular weight compound.
- the molecular weight is, for example, lower than 2,000 g/mol or than 1,000 g/mol.
- the disulphide is employed, for example, in a concentration of from 5 mM to 1 M, in particular 10 mM to 0.5 M.
- the disulphide compound is glutathione disulphide.
- Glutathione also ⁇ -L-glutamyl-L-cysteinylglycine, is a pseudo-tripeptide which is formed from the three amino acids glutamic acid, cysteine and glycine.
- GSH is present in the cytoplasm of both prokaryotes and eukaryotes and is involved in the formation of disulphide bridges. It is in equilibrium with the dimer GSSG, which contains a disulphide bridge.
- Glutathione reacts with cysteines R—SH and R′—SH from two polypeptides or from a single polypeptide in a disulphide exchange reaction:
- RSSG is called a mixed disulphide. It is reacted with a further cysteine of a polypeptide, so that as a result a disulphide bridge is obtained between two cysteines:
- Glutathione is kept enzymatically in the reduced form (GSH) in the cytosol. “Reducing conditions” in the cytosol are therefore referred to. Conditions are established in the solubilization buffer so that the disulphide compound it comprises catalyses the formation of disulphide bridges in accordance with the reactions described above.
- the GSSG is employed, for example, in a concentration of from 10 mM to 0.5 M.
- Cysteine might be used as reducing agent (reductant).
- the denaturation solution is a Tris buffer.
- the denaturation solution can comprise further conventional additives, for example EDTA or salts.
- the pH of the solubilization buffer is, for example, between 7 and 10, preferably pH 8.
- the solubilization is preferably assisted mechanically, for example with conventional homogenization apparatuses or by means of ultrasound. After the solubilization, solids which remain are preferably separated off The supernatant comprises the solubilized pro-NGF.
- the denaturing solution comprises
- a concentration of 4 M Guanidinium-HCl is in most cases sufficient for a complete denaturation of proNGF mutein.
- Step b Refolding of the proNGF Mutant
- step b) transferring the proNGF mutant into a refolding buffer occurs where the denatured proNGF assumes a biologically active conformation.
- a biologically active conformation can be determined by the presence of disulfide bridges occurring in natural beta-NGF.
- the solubilized proNGF mutant is renatured in a refolding solution which contains at least one chaperone, at least one a metal chelator, and a redox shuffling system.
- the method according to the present invention uses a refolding solution in step b) comprising
- the folding assistant is Arginine.
- Compounds which promote the folding of proteins can generally be employed as “folding assistants”. Such compounds are known to the person skilled in the art. They can assist the folding in various ways. It is assumed that arginine destabilizes incorrectly folded intermediates, so that these are at least partly unfolded again (from a thermodynamic dead-end) and therefore can be correctly folded again. On the other hand, glycerol usually stabilises proteins.
- the refolding is preferably carried out at a pH of between 8 and 11, in particular pH 9.5.
- a pulse renaturation was carried out. Limiting for the number of pulses is the Guanidinium-HCl concentration which should not exceed 0.3 M. The protein concentration per pulse should not exceed 50 ⁇ g/ml in relation to the final refolding volume.
- the solubilisate is added to the folding batch in several fractions or continuously over several days.
- the solubilisate is added in a “pulse renaturing” by rapid dilution to the solubilisate.
- at least 6 pulses could be performed in a time interval of, for example, 24 hours.
- the number of pulses is set such that after the addition of the solubilization batch the concentration of protein which has not yet been folded is not too high, since otherwise aggregates are obtained.
- each pulse 0.05 g/l to 0.2 g/l preferably 0.1 g/l of protein is newly transferred into the folding batch (based on the protein concentration in the folding batch after addition of the solubilisate).
- each refolding step takes at least 1-2 h.
- the refolding reaction needs to be clarified before loading onto a column. This can be done by any methods known in the art, for example, by filtration.
- the method for producing a correctly folded pro-NGF mutant includes the following steps: a) Inclusion bodies which comprise insoluble proNGF mutant are solubilized in a denaturing solution as described above, and b) the solubilized pro-NGF is then renatured in a refolding solution buffer as described above.
- the denaturing solution and/or the refolding solution consequently contains no detergent. It has been found, that the use of detergents is not necessary for the solubilization and/or folding of pro-NGF mutein. This is advantageous, since certain detergents are comparatively aggressive chemical substances which pharmaceutical products should not comprise or should comprise in only small amounts and therefore must be removed in an expensive manner.
- the method according to the invention is therefore advantageous compared with the method of Soejima et al., 2001, in which such aggressive detergents (Triton X-100 or Brij-58) are employed for folding the protein. In other words, no detergents are used in the entire production method according to the invention, and the production method is therefore detergent-free.
- Step c Purification of proNGF Mutant by Chromatography
- an aqueous solution of folded pro-NGF mutein is obtained.
- the folded pro-NGF mutein can subsequently be purified further by known methods.
- the proNGF mutant is purified from the refolding (e.g. non- or weak denaturing) solution via chromatographic purification, in particular by means of a mixed mode chromatography (step c of the method of production of beta NGF from a proNGF mutant of the invention).
- the most preferred column for the chromatography is a column with a synthetic affinity ligand, preferably 4-mercapto-ethyl-pyridine (MEP Hypercell; Pall).
- MEP Hypercell 4-mercapto-ethyl-pyridine
- MEP Pall; affinity ligand is 4-Mercapto ethyl pyridine
- HEA Pall; affinity ligand: Hexylamino
- PPA Pall, affinity ligand: Phenylpropylamino
- MBI Pall; affinity ligand: 2-Mercapto-5benzamidazole sulfo acid
- Capto MMC GEHC
- Capto adhere GEHC; affinity ligand: N-benzyl-N-methyl ethanolamine
- CHT hydroxyapatite BioRad
- CHT fluoroapatide CHT fluoroapatide
- the MEP, HEA, PPA, and MBI columns have a hydrophobic binding, where Capto MMC is a cation exchanger with mixed mode functionality and Capto adhere is an anion exchanger with mixed mode functionality.
- the BioRad columns are ion exchange columns with hydrophobic components. Any other mixed mode material column not listed here could also be used to purify the proNGF mutant.
- Step d Cleavage of proNGF to Beta-NGF
- proNGF is the precursor of beta-NGF.
- step d) of the method of production of beta-NGF from a proNGF mutant of the invention the pro-sequence of the proNGF mutant is cleaved in order to obtain an active beta-NGF.
- Proteases having trypsin-like substrate specificity cleave the protein without digesting the active portion of the protein molecule.
- Trypsin-like proteases cleave peptide bonds following a positively charged amino acid such as Arginine or Lysine.
- trypsin-like proteases several serine proteases (serine endopeptidases) are considered for processing of the proNGF to result beta-NGF.
- the serine protease Trypsin is used for the cleavage of the pro-sequence but other proteases could be used instead.
- cleavage is not restricted to trypsin itself, but may involve other proteases having trypsin-like substrates as well. Generally, if the ratio of proNGF to trypsin (or other protease) is appropriately adjusted, the correctly folded, mature beta-NGF will not be cleaved by this protease. In contrast, denatured proteins as well as folding intermediates expose sequences which are susceptible to an attack by the protease.
- the ratio of trypsin (or other protease) to proNGF mutant is from 1:200-1:100.000, more preferably from 1:5.000-1:20.000 per weight, most preferred is a ratio of 1:10.000 (w/w).
- the cleavage occurs for 8-23 hours at room temperature, most preferred 18 hours. Under the conditions used in this invention, proNGF mutant is cleaved completely and almost no by-products are formed. No aggregation was observed.
- the present inventors have found that the amino acid modifications introduced in the proNGF mutant of the invention not only avoid cleavage of the protein at undesired cleavage sites but also unexpectedly result in a great increase in the efficiency of the cleavage of Trypsin compared to that of the wild type proNGF, which allows to carry out the cleavage under very selective conditions to obtain a very pure product.
- the experimental data clearly show that at already a very low Trypsin/Protein ratio such as 1:100.000, the proNGF mutant of the invention (SEQ ID NO: 5) results in very high purity recombinant human beta-NGF with a high cleavage yield (about 85%). Furthermore, wild type proNGF (SEQ ID NO: 1) at the same Trypsin/Protein ratio shows a low cleavage yield (about 5%). A satisfactory yield is only obtained at much higher trypsin/protein ratios (1/250), but this is accompanied by low selectivity and a high product degradation due to overdigestion.
- the beta-NGF produced from a proNGF mutant of the invention is further purified, for example, by several chromatographic methods. Further purification steps are required to separate Trypsin and product related impurities of the tryptic digestion from beta-NGF. Purification steps should reduce HCPs, Endotoxins, and DNA. Any methods known in the art for protein purification can be used. Most preferred are chromatographic purifications, for example with Sepharose columns (e.g. SP Sepharose HP, Q Sepharose FF).
- the final product beta-NGF produced from a proNGF was analyzed regarding its purity by SDS-PAGE, rp-HPLC, SE-HPLC, and IEX-HPLC. HPLC analyses revealed a purity of beta-NGF of at least 97%.
- the method for the production of a pro-NGF mutein suitable for obtaining beta-NGF includes the following steps:
- the invention is directed to the use of the proNGF mutant of the present invention for producing human beta-NGF.
- the invention is directed to a pharmaceutical composition
- a pharmaceutical composition comprising betaNGF obtained from a proNGF-mutant being substituted at the native protease cleavage site R 1 SK 3 R 4 at positions 101 and 103 (K 3 and R 1 ) of the human wildtype proNGF sequence (SEQ ID NO: 1) as described above and a pharmaceutically acceptable carrier.
- the pharmaceutically active beta-NGF is administered to the patient by gene-therapeutical methods.
- gene therapy there are two basic methods available, suitable for introducing a gene, in the present case a gene coding for a beta-NGF, into the patient.
- the pharmaceutically active gene encoding beta-NGF is introduced in a body cell by a vector, where the body cell preferably is a glial cell, and the cell treated in this way then is re-introduced into the patient, for example by micro- or nanoparticles.
- the body cell preferably is a glial cell
- the cell treated in this way then is re-introduced into the patient, for example by micro- or nanoparticles.
- Particularly preferred is a specific integration of the beta-NGF gene in the cellular genome.
- the beta-NGF gene is transported to target cells in the body by vectors, for example by means of viruses, which on the one hand may infect the target cell und, thus, will be able to introduce the pharmaceutically active beta-NGF gene, but, on the other hand, are not able to reproduce themselves within the target cell.
- vectors for example by means of viruses, which on the one hand may infect the target cell und, thus, will be able to introduce the pharmaceutically active beta-NGF gene, but, on the other hand, are not able to reproduce themselves within the target cell.
- nano- or microparticles for example liposomes, which may fuse with the cell membrane, may be used a vectors as well.
- a virus or an antibody might be used as an example, capable of specifically infecting the host cell or which immunoreacts with an antigen in the target cell.
- retroviruses might be used as an example.
- adenoviruses or Vaccinia based vectors for example, modified vaccinia virus Ankara (MVA).
- the pharmaceutical composition might comprise one or more pharmaceutically acceptable ingredients, for example carriers or diluents.
- pharmaceutically acceptable ingredients for example carriers or diluents.
- these classes of substances one might name fillers, salts, buffers, stabilisators, penetration enhancers and other well-known materials.
- Techniques for the formulation of pharmaceutical compositions of the present invention may be found in well-known standard textbooks such as “Remington's Pharmaceutical Sciences”, Mack Publishing Co., Easton, Pa., latest edition.
- the dosage of the betaNGF obtained by the method of production as described in the present invention might be in a range of 0.1 ⁇ g/kg to 500 ⁇ g/kg body weight, if administered by infusion, and from 2 ⁇ g/kg to 2 mg/kg body weight if administered by injection.
- FIG. 1 shows the sequence of pro-NGF and of the pro-NGF mutants of the invention. Shown in bold letters is the sequence of the proform of human beta-NGF. Shown in bold and underlined is the protease (trypsin) cleavage site (amino acids 101-104 of SEQ ID NO: 1; trypsin cleavage sites are between amino acids 101-102 (R 1 ), 103-104 (K 3 ) and 104-105 (R 4 )).
- X in the sequence can be any amino acid.
- FIG. 1 a shows a sequence of human proNGF (SEQ ID NO: 1) with protease cleavage site RSKR (SEQ ID NO: 9).
- FIG. 1 b shows a sequence of a proNGF mutant of the invention (SEQ ID NO: 2) with the protease cleavage site VSXR (SEQ ID NO: 10).
- FIG. 1 c shows a sequence of a proNGF mutant of the invention (SEQ ID NO: 3) with the protease cleavage site mutated to XSXR (SEQ ID NO: 11).
- FIG. 1 d shows a sequence of a proNGF mutant of the invention (SEQ ID NO: 4) with the protease cleavage site mutated to XSAR (SEQ ID NO: 12).
- FIG. 1 e shows a sequence of a proNGF mutant of the invention (SEQ ID NO: 5) with the protease cleavage site mutated to VSAR (SEQ ID NO: 13).
- FIG. 1 f shows a sequence of a proNGF mutant of the invention (SEQ ID NO: 7) with the protease cleavage site mutated to XXXR (SEQ ID NO: 14).
- FIG. 1 g shows a sequence of a proNGF mutant of the invention (SEQ ID NO: 8) with the protease cleavage site mutated to VXAR (SEQ ID NO: 15).
- FIG. 1 h shows sequences of protease cleaving sites (SEQ ID NO:s 6, 9-15).
- FIG. 2 Processing of proNGF or pro NGF mutants to beta-NGF
- FIG. 2 a shows six beta NGF cleavage products after trypsin cleavage by using the wild type proNGF having a native furin cleavage site RSKR.
- the drawing clearly shows that a cleavage of wild type proNGF to betaNGF results in an inhomogenous mixture of many different cleavage products.
- FIG. 2 b shows native beta NGF cleavage products after trypsin cleavage by using a proNGF mutant SP174-101 (SEQ ID NO: 5) with deletion of the native furin cleavage site.
- the protease cleavage site RSKR (SEQ ID NO: 9) was substituted by two amino acids to result a site VSAR (SEQ ID NO: 12). This site can only be cleaved by a protease after the amino acid Arginine in position 104; Trypsin can only cleave at one cleavage site (instead of three).
- the drawing clearly shows that a cleavage of mutant proNGF SP174-101 (SEQ ID NO: 5) to beta-NGF results in only one homogenous cleavage product (beta-NGF).
- FIG. 3 shows the refolding of the proNGF mutant SP174-101 (SEQ ID NO: 5) compared to wild type proNGF.
- the figure compares the refolding yield of the wild type proNGF (continuous line) and the proNGF mutant (broken line) with the protease cleavage site mutated to VSAR. It can be clearly seen from the figure that the refolding efficiency of wild type and mutant proNGF is identical.
- FIG. 4 shows the purification of a proNGF mutant SP174-101 with the protease cleavage site mutated to VSAR (SEQ ID NO: 5) by a MEP HyperCel column.
- the figure shows an elution profile of MEP HyperCel purification of a refolded and filtrated proNGF mutant.
- FIG. 5 shows the cleavage of a proNGF mutant SP174-101 with the protease cleavage site mutated to VSAR (SEQ ID NO: 5) by Trypsin.
- the figure shows a Coomassie stained SDS-PAGE gel of fractions of the tryptic cleavage.
- the tryptic cleavage product of the proNGF mutant can be seen in lanes 4-7.
- the figures clearly show that the purified proNGF mutant results in only one cleavage product (beta-NGF).
- FIG. 6 shows the purification of beta-NGF.
- the figure shows a profile of a SP Sepharose HP column after the tryptic cleavage.
- the tryptic digestion reaction was loaded onto a SP Sepharose HP column.
- the elution was done in three steps (a. 25% 25 mM sodium phosphate, 1 M NaCl, pH 6.5 (buffer B), b. in a linear gradient from 25-50% buffer B, and c. 100% buffer B (flow rate 60 cm/h)).
- FIG. 7 shows the structure of the proprietary expression vector pSCIL1101.
- the bacterial host E. coli JM108 used for expression of rh-proNGF (DSMZ 5585; F thi ⁇ (lac-proAB) end AI gyrA 96 relA1 phx hsdR17 supE44 recA) is proline-auxotrophic, which was neutralized by the use of the plasmid with the designation pSCIL101.
- the plasmid pSCIL101 is based on the plasmid pSCIL008 (see WO05061716). The strain cannot synthezise thiamine (Vieira & Messing, 1982 Gene. Oct; 19(3): 259-68).
- the pro-NGF mutant shown in SEQ ID NO: 5 is expressed under the control of the tac promoter located on pSCIL101.
- the vector pSCIL101 used here is a high copy plasmid with a kanamycin resistance. The expression is carried out in defined mineral salt medium and is induced by the addition of IPTG.
- the pro-NGF mutant is deposited in the cytosol in the form of inclusion bodies (IBs).
- the aim of this fermentation was to obtain product and biomass for subsequent process steps.
- samples were analyzed by means of SDS-PAGE before and after induction.
- the recombinant protein is present in the form of aggregates.
- the expression of the pro-NGF mutein took place in the form of IBs.
- the cell breakdown and the IB preparation were carried out in accordance with standard protocols and can be conducted on the laboratory scale up to a working up of approx. 200 g of biomass.
- the preparation of these “inclusion bodies” containing the proNGF mutein was performed according to Rudolph, R., et al. (1987); Folding proteins. In: Creighton, T. E. (ed.): Protein Function: A Practical Approach. Oxford University Press, pp. 57-99, and according to EP0994188B1.
- the cell pellets were resuspended in a suitable buffer and subsequently the cells were disrupted using high pressure homogenization in 50 mM Natriumphosphat pH 7.0, 1 mM EDTA.
- the inclusion bodies were solubilized in a denaturing solution which comprised a solution (i) a chaotropic agent, (ii) a chelator, (iii) a buffer, and (iv) a reducing agent.
- a denaturing solution which comprised a solution (i) a chaotropic agent, (ii) a chelator, (iii) a buffer, and (iv) a reducing agent.
- Guanidinium HCl (GuaHCl) was tested in a concentration range of 4.0-6.0 M.
- the solubilization buffer was mixed in different ratios with a inclusion-body slurry (IB slurry). All experiments had a final Cysteine concentration of 5 mM and were carried out at room temperature. Results were analyzed by SDS-PAGE (data not shown). The experiments revealed that a concentration of 4 M GuaHCL was sufficient for complete solubilization of inclusion bodies.
- the ratio of inclusion body-slurry to buffer is 1
- the solubilisate is clarified by depth filtration according to standard procedures.
- the protein concentration was then determined using the method of Bradford (Bradford, M. M., Anal. Biochem. 72 (1976) 248).
- the protein concentration of proNGF mutein was between 10-20 mg/ml.
- NGF in the active conformation was confirmed by the presence of the disulfide bridges occurring in mature human beta-NGF.
- a pulse renaturation was carried out. A pulse was given every hour per 50 ⁇ g/ml proNGF mutant protein. The concentration of Guanidinium-HCl in the solution should not exceed 0.3 M. In order to achieve this, 15 pulses were required. The clarified refolded fraction was filtered before loading to further columns.
- the performance of the refolding reaction was analysed after every pulse by rp-HPLC. The resulting peak area was blotted against the number of pulses.
- a reversed-phase column e.g., 214MS54, 4.6 ⁇ 250 mm; 300 ⁇ , 5 ⁇ m, Vydac
- guard column e.g. 214GK54; 300 ⁇ ; Vydac
- the running buffers were H 2 O with 0.05% trifluoroacetic acid (TFA) and Acetonitrile with 0.05% TFA.
- the flow rate was 1 mL/min. Results are shown in FIG. 3 . It can be seen from FIG. 3 that the refolding efficiency of wild type and mutant proNGF is identical.
- a column with a synthetic affinity ligand, 4-mercapto-ethyl-pyridine (MEP) was used. The elution was done by shifting the pH-value. Further, elution was carried out with a low salt concentration which is beneficial for an efficient process design.
- the column was equilibrated with 0.75 M Arginine, 5 mM EDTA, pH 9.5.
- the clarified refolding reaction was loaded onto MEP HyperCel column (Pall) with a maximal loading capacity of 5 g proNGF mutant per L column media.
- MEP HyperCel column Pall
- most impurities and unbound protein were depleted by using buffer 2 M GuaHCl, 0.1 M Tris-HCl, pH 8.0 and 10 mM Tris-HCl, pH 8.0.
- the elution was done in a linear gradient from 0-70% 50 mM Acetate, pH 4.0 (flow rate 120 cm/h).
- FIG. 5 shows an SDS-PAGE of fractions of the tryptic cleavage.
- Lanes 5-7 show the tryptic cleavage products compared to the uncleaved proNGF mutant (rhproNGF*, see lane 3) and to the mature beta-NGF (NGF; see lane 8).
- the figures clearly show that the purified proNGF mutant results in only one cleavage product (beta-NGF). A complete digestion of proNGF mutant to beta-NGF could be observed.
- beta-NGF was loaded onto a SP Sepharose HP column to deplete Trypsin, by-products of the cleavage and further impurities.
- the SP Sepharose HP purification is shown in FIG. 6 .
- the column was equilibrated with 25 mM Na-phosphate buffer (pH 6.5).
- the tryptic digestion reaction was loaded onto a SP Sepharose HP column (2 g beta-NGF/L medium) and unbound protein washed with the equilibration buffer.
- the elution was done in three steps (3 cv 25% 25 mM Na-phosphate pH 6.5/1 M NaCl (buffer B), 10 cv in a linear gradient from 25-50% buffer B, and 3 cv 100% buffer B (flow rate 60 cm/h)).
- FIG. 6 shows the purification of beta-NGF.
- the figure shows a profile of a SP Sepharose HP column after the tryptic cleavage.
- the yield of beta-NGF was 85-95% (peak “sample elution”).
- Mass ratio 1/10.000 w/w of trypsin/rhProNGF mutant was used, while different mass ratios of trypsin/rhProNGF wild type were used (see Table 3).
- As per trypsin solution 1.0 ⁇ g/mL and 10 ⁇ g/mL were used. After an overnight incubation (about 17 hours) at room temperature, all samples were analysed. For control porpoises rhProNGF mutant without added protease was also incubated.
- Table 4 shows the cleavage yields obtained after tryptic digestion.
- the experimental data clearly show that cleavage of the proNGF mutant SEQ ID NO: 5 with Trypsin results in only one product (beta-NGF) at high cleavage yield (about 85%) using a very low trypsin/protein ratio (1/10.000).
- This can be compared to the cleavage of the wildtype proNGF (SEQ ID NO: 1) which shows a low cleavage yield (only about 5%) at low trypsin/protein ratio (1/10.000) and a high product degradation (overdigested) at high trypsin/protein ratio (1/250).
- TF1 cells (ATCC, catalog nr. CRL2003) were cultivated according to standard procedures.
- a test medium (90% medium RPMI 1640, 10% foetal bovine serume FBS, 50 U/ml Penicillin und 50 ⁇ g/ml Streptomycin) was added to the cells and centrifuged. The pellet was resuspended at a density of 1.5 ⁇ 10 5 cells/ml in test medium at 37° C.
- the cell suspension was mixed with different concentrations of proNGF protein (10 ⁇ M, 3 ⁇ 10 ⁇ 10 M, 10 ⁇ 9 M, 3 ⁇ 10 ⁇ 9 M, 10 ⁇ 8 M, 3 ⁇ 10 ⁇ 8 M, 10 ⁇ 7 M, 3 ⁇ 10 ⁇ 7 M, 10 ⁇ 6 M, 3 ⁇ 10 ⁇ 6 M, 10 ⁇ 5 M und 3 ⁇ 10 ⁇ 5 M) and analyzed in 96-well-plates. After incubation for 48 h at 37° C., cell proliferation reagent (e.g. WST-1, Roche Applied Science, cat no. 1644807) was added and the plates again incubated for 4 h at 37° C. The absorption was measured at 450 nm and the EC 50 -value determined by using suitable programs (z. Bsp. Sigma-Plot 2000).
- proNGF protein 10 ⁇ M, 3 ⁇ 10 ⁇ 10 M, 10 ⁇ 9 M, 3 ⁇ 10 ⁇ 9 M, 10 ⁇ 8 M, 3 ⁇ 10 ⁇ 8 M, 10 ⁇
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Ophthalmology & Optometry (AREA)
- Analytical Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- This application is a divisional of U.S. application Ser. No. 14/978,407 filed Dec. 22, 2015, which is a divisional of U.S. patent application Ser. No. 14/366,460 filed Jun. 18, 2014, and issued as U.S. Pat. No. 9,617,322 on Apr. 11, 2017, which is a 35 U.S.C. 371 National Stage Patent Application of International Application No. PCT/EP2012/076251, filed Dec. 19, 2012, which claims benefit of priority to European application 11194208.2, filed Dec. 19, 2011; the contents all of which are hereby incorporated by reference. The sequence listing in parent application Ser. No. 14/366,460 is also incorporated by reference herein.
- The present invention relates to novel proNGF mutants having substitutions at the native protease cleavage site. The present invention further discloses a method of producing a biologically active human beta-NGF from an inactive insoluble proNGF mutant and the use of a proNGF mutant for producing human beta-NGF.
- Nerve growth factor (beta-NGF) is a neurotrophic factor playing a crucial role in the growth and survival of neurons (sensory and sympathetic) (Levi-Montalcini, R., Science 237 (1987) 1154; Thoenen, H., et al., Physiol. Rev. 60 (1980) 1284; Yankner, B. A., et al., Annu. Rev. Biochem. 51 (1982) 845). Beta-NGF belongs to a cysteine-knot superfamily of growth factors assuming stable dimeric protein structure. Furthermore, beta-NGF promotes the growth, differentiation and vitality of cholinergic neurons of the central nervous system (Hefti, F. J., J. Neurobiol. 25 (1994) 1418). Possible therapeutic indications for recombinant human nerve growth factor include peripheral sensory neuropathies, e.g. associated with diabetes or as a possible side effect in AIDS therapy. Other indications for beta-NGF are central neuropathies, e.g. Alzheimer's disease. In this case, the loss of memory is the result of a loss of cholinergic neurons. Beta-NGF has also been found to be effective in the treatment of human cutaneous and corneal ulcers (Beniabei et al. Lancet 1999; Lambiase et al. NEJM 1998). Moreover. Beta-NGF has also been shown to protect retinal cells from degeneration and apoptosis in an experimental animal model of glaucoma and to improve visual function in a few patients affected by glaucoma (Lambiase A, et al. PNAS 2009).
- Mature human beta-NGF is a 118 amino acid protein which is translated as a preproprotein consisting of 241 amino acids. The signal peptide (prepeptide) of 18 amino acids is cleaved during translocation into the endoplasmic reticulum (ER). The resulting proprotein (proNGF) is processed at its N-terminus by removing the pro-sequence by protease cleavage. Mature human NGF shows a high degree of identity (about 90%) to rodent (murine and rat) beta-NGF. For clinical studies or therapeutic uses, beta-NGF has to be provided in high concentrations. Submaxillary glands of mice are a natural source of beta-NGF. However, these beta-NGF preparations are heterogeneous mixtures of different dimers and thus not suitable for therapeutic uses. Furthermore, it is desirable to administer the human form of the protein to patients. In human tissue, however, neurotrophic factors are present only in low concentrations.
- The prosequence is a domain separate from the mature protein (see the sequence data in
FIG. 1 , wherein the prosequence is indicated in bold). These two domains are separated by an exposed protease cleavage site with a basic amino acid target sequence of the type Arg-Ser-Lys-Arg located atpositions 101 to 104 of the human proNGF sequence (SEQ ID NO: 1). This motif is naturally a cleavage site for the serine endoprotease Furin. Additionally, the cleavage site may be specifically processed by other suitable proteases, preferably by proteases with substrate specificity of cleavage after the amino acid Arginine (Arg, R). For example, the protease trypsin cleaves after basic amino acids such as Lysine (Lys, K) or Arginine (Arg, R). - Methods for the preparation of biologically active beta-NGF from its inactive proform are well-known in the field of the art. For example,
EP 0 994 188 B1 describes a method for the preparation of biologically active beta-NGF from its inactive pro-form having a poor solubility. According to this method, beta-NGF is obtainable from recombinant insoluble inactive proNGF which solubilized in a denaturing solution. Afterwards, the solubilized proNGF is transferred into a non- or weakly denaturing solution. The denatured proNGF assumes a biologically active conformation as determined by the disulfide bonds present in native beta-NGF. Subsequently, the prosequence of proNGF is cleaved off whereby active beta-NGF is obtained. - Human proNGF contains a native protease (Furin) cleavage site Arg-Ser-Lys-Arg, thus having the following sequence motif: R1SK3R4. For specific production processes such as those requiring “Good Manufacturing Practice” (GMP) quality levels, materials such as enzymes have to be provided in high quality. The protease Furin is currently not available as GMP-grade protease.
- Therefore, an alternative protease, Trypsin (EC 3.4.21.4), was chosen to cleave proNGF to result in a mature beta-NGF protein. The serine protease Trypsin cleaves peptide chains at the carboxyl side of basic amino acids Arginine or Lysine. In human proNGF, the naturally occuring cleavage site in human proNGF contains three positions with basic amino acids (
positions 101, 103, and 104 of SEQ ID NO: 1; alternatively referred to as R1, K3 and R4 herein). Thus, cleavage of proNGF by Trypsin may lead to numerous different cleaved products depending on where exactly cleavage occurs. Typical cleavage products are SK3R4-beta-NGF and R4-beta-NGF and mature beta-NGF. This problem is exacerbated since dimerization of the beta-NGF protein will lead to an even higher number (up to six) of inhomogenous products which have to be purified in following steps (seeFIG. 2a ). - Methods for producing betaNGF have been described in the prior art. However, the currently available production processes have several drawbacks, such as inhomogenous beta-NGF products and low yields of beta-NGF.
- Cleavage of the wild-type pro-NGF with Trypsin to produce beta-NGF has shown low efficiency that obliges to use very high amounts of the enzyme in order to obtain a sufficient yield of cleaved beta-NGF. This has several drawbacks that impact on the subsequent process of purification. First of all, it further decreases the selectivity of the cleavage which leads to several products of digestion. Secondly, the purification of beta-NGF from the enzyme is necessary since the enzyme has to be absent in the final sample of the protein. This implies several purification procedures to remove the abundant Trypsin. Thus, the use of Trypsin as cleavage enzyme in the procedure of the prior art leads either to very low yields of beta-NGF or to problems of purification of the protein.
- Needless to say that there remains a need in the art for a method of producing beta-NGF without the drawbacks as described above. It is thus a problem underlying the present invention to provide a novel method of producing beta-NGF to be obtained in high quality, high efficiency and in high yields. Further, it is a problem underlying the invention to provide a production process for beta-NGF which results in high yields of beta-NGF, is efficient, robust, scalable and reproducible.
- An advantage of the invention is the production of a beta-NGF from a novel proNGF mutant. The novel mutant results in homogenous beta-NGF products in good yield because the novel proNGF mutant prevents inhomogeneous digestion by proteases and thus inhomogenous beta-NGF products. The problem of the invention is solved by providing the proNGF mutant of the invention and the method of producing beta-NGF from the proNGF mutant as described by the present invention.
- The novel mutant results in an unexpected and striking increase in the efficiency of the cleavage of trypsin at the relevant site in the mutated proNGF of the invention compared to the wild type. This allows to use extremely low amounts of the protease trypsin as compared to the amount to be used on the wild type and, as a consequence, results in reduced problems of purification of beta NGF from the enzyme itself and from by products of the cleavage.
- The above-described problems are solved and the advantages are achieved by the subject-matter of the independent claims. Preferred embodiments of the invention are included in the dependent claims as well as in the following description, examples and figures.
- The above overview does not necessarily describe all problems solved by the present invention. Further problems and how there are solved may be apparent for the skilled person after having studied the present application.
- In a first aspect the present invention relates to a proNGF mutant, wherein the protease cleavage site R1SK3R4 is substituted at least at positions R1 and K3 corresponding to
positions 101 and 103 of the human wildtype proNGF sequence (SEQ ID NO: 1) by an amino acid selected from non-basic amino acids and Histidine. - In a second aspect the present invention relates to a method of preparing a biologically active human beta-NGF from an inactive insoluble proNGF mutant substituted at the native protease cleavage site R1SK3R4 at least at positions R1 and K3 corresponding to
positions 101 and 103 of the human wildtype proNGF sequence (SEQ ID NO: 1), comprising (i) providing a proNGF mutant according to this invention, and (ii) cleaving the proNGF mutant in order to obtain active human beta-NGF. - In particular, the invention relates to the following process:
-
- a. dissolving the proNGF mutant in a denaturating solution;
- b. transferring the proNGF mutant into a refolding solution where the denatured proNGF assumes a biologically active conformation;
- c. purifying the proNGF mutant from the refolding solution;
- d. cleaving the pro-sequence of the proNGF mutant to obtain the active beta-NGF.
- A third aspect of the invention relates to the use of a proNGF mutant wherein at least Arginine at
position 101 and the Lysine at position 103 of the native protease cleavage site R1SK3R4 atpositions 101 to 104 of the human wildtype proNGF (SEQ ID NO: 1) is substituted by non-basic amino acids for the preparation of human beta-NGF. - A further aspect of the present invention relates to pharmaceutical compositions comprising beta-NGF produced from the proNGF mutant wherein at least Arginine at
position 101 and Lysine at position 103 of the native protease cleavage site R1SK3R4 atpositions 101 to 104 of the human wildtype proNGF (SEQ ID NO: 1) are substituted by an amino acid selected from non-basic amino acids and Histidine and a pharmaceutically acceptable carrier or diluent. - This summary of the invention does not necessarily describe all features of the present invention. Other embodiments will become apparent from a review of the ensuing detailed description.
- Definitions
- Before the present invention is described in detail below, it is to be understood that this invention is not limited to the particular methodology, protocols and reagents described herein as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs.
- Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising”, will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integer or step.
- Several documents (for example: patents, patent applications, scientific publications, instructions etc.) are cited throughout the text of this specification. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
- Sequences: All sequences referred to herein are disclosed in the attached sequence listing that, with its whole content and disclosure, is a part of this specification.
- The term “about” when used in connection with a numerical value is meant to encompass numerical values within a range having a lower limit that is 5% smaller than the indicated numerical value and having an upper limit that is 5% larger than the indicated numerical value.
- The term “proNGF” or “pro-NGF” refers to the pro-form of human beta-NGF. The full human proNGF sequence is defined in SEQ ID NO: 1 (
FIG. 1a ). In order to obtain mature beta-NGF, the propeptide proNGF has to be cleaved by proteases. The prosequence of beta-NGF is a domain separate from the mature beta-NGF. Between these two domains, there is a native protease cleavage site Arg-Ser-Lys-Arg (referred herein to R1SK3R4, SEQ ID NO: 9) atpositions 101 to 104 of SEQ ID NO: 1. The cleavage site may be specifically processed by suitable proteases, in particular furin protease. - The term “proNGF mutant” or “proNGF mutein” refers to modifications of the pro-form of human beta-NGF by substitutions of amino acids. The proNGF mutein of the present invention is substituted at the native protease cleavage site R1SK3R4 (SEQ ID NO: 9) at least at both positions K3 and R1 corresponding to
positions 101 and 103 of the human wild type proNGF sequence (SEQ ID NO: 1) by an amino acid selected from non-basic amino acids and Histidine. - In a preferred embodiment of the invention, amino acid Lysine in Position K3 (corresponding to position 103) is substituted with Alanine (see
FIG. 1 d, SEQ ID NO: 4,FIG. 1 e, SEQ ID NO: 5,FIG. 1g , SEQ ID NO: 8). - In another preferred embodiment of the invention, amino acid Arginine in position R1 (corresponding to position 101) is substituted with Valine (see
FIG. 1 b, SEQ ID NO: 2,FIG. 1 e, SEQ ID NO: 5,FIG. 1 g, SEQ ID NO: 8). - In another embodiment of the invention, the amino acid arginine R4 corresponding to position 104 of the wildtype proNGF sequence (SEQ ID NO: 1) may also be substituted by any amino acid which allows processing of the proNGF by proteolytic cleavage to obtain beta NGF, preferably a basic amino acid such as Arginine or Lysine. For example, the presence of Alanine in Position R4 avoids processing of proNGF to beta NGF. Therefore, the mutant of invention cannot contain Alanine in position 104.
-
TABLE 1 Protease cleavage sites of pro NGF and proNGF muteins (X refers to any amino acid but not Arg or Lys) Protease cleavage site SEQ ID NO: (pos. 101-104 of SEQ ID NO: 1) 1 RSKR (wild-type) 2 VSXR 3 XSXR 4 XSAR 5 VSAR 6 XXXR 7 VXAR - The term “non-basic amino acid” refers to any amino acid which is not positively charged. The term refers to an amino acid residue other than a basic amino acid. The term excludes amino acids Lysine or Arginine which are amino acids with positive side chains. Non-basic amino acids are negatively charged amino acids Glutamic Acid and Aspartic Acid, amino acids with polar uncharged side chains (Serine, Threonine, Asparagine, Glutamine), amino acids with hydrophobic side chains (Alanine, Valine, Isoleucine, Leucine, Methionine, Phenylalanine, Tyrosine, Tryptophane) and amino acids Cysteine, Glycine and Proline.
- The term “biologically active pro-NGF” or “proNGF with biologically active conformation” as such refers to the biological activity of pro-NGF. A biologically active conformation of proNGF is determined by the presence of disulfide bridges occurring in natural beta-NGF. The activity may be, for example, determined according to an assay as described by Chevalier et al. 1994, Blood 83: 1479-1485, 1994, which is incorporated herein by reference. Example 11 describes an assay for the biological activity of proNGF via stimulation of the proliferation of TF1 cells.
- The term “beta-NGF” refers to a mature beta-nerve growth factor, preferably from human. The sequence for the mature beta-nerve growth factor is shown in
FIG. 1 (SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, SEQ ID NO: 7, and SEQ ID NO: 8), starting at position 105. - The term “activity of beta-NGF” or “biologically active beta-NGF” as such means the biological activity of beta-NGF. Biologically active beta-NGF exists in the form of a dimer. Beta-NGF must be present in a dimeric form to have a biologically active conformation. The prerequisite of a biologically active conformation of beta-NGF is the correct formation of the disulfide bridges to a cystine knot. The activity may be, for example, determined according to the DRG assay (dorsal root ganglion assay), see for example Levi-Montalcini, R. et al., Cancer Res. 14 (1954) 49, and Varon, S. et al., Meth. in Neurochemistry 3 (1972) 203. In this assay the stimulation and survival of sensory neurons from dissociated dorsal root ganglia of chick embryos is monitored by means of neurite formation.
- The term “substitution” or “substitutions” refers to modifications of the pro-form of human beta-NGF by replacement of amino acids. The term comprises the chemical modification of amino acids by e.g. substituting or adding chemical groups or residues to the original amino acid. The step of modification of the selected amino acids is performed preferably by mutagenesis on the genetic level. Preferably, the modification of proNGF is carried out by means of methods of genetic engineering for the alteration of a DNA belonging to proNGF. The modifications are mutations that cause the replacement of a single base nucleotide with another nucleotide of the genetic material. Point mutations results in encoding different amino acids compared to the wild-type sequence. Preferably, expression of the modified proNGF protein is then carried out in prokaryotic or eukaryotic organisms, most preferably in prokaryotic organisms.
- The term “denaturating” or “denaturation” refers to a process in which the folding structure of a protein is altered. The term refers to unfold the tertiary structure of proNGF or proNGF mutein. The alteration of the folding structure is due to exposure to certain chemical or physical factors. As a result, some of the original properties of the protein, especially its biological activity, are diminished or eliminated. Due to the denaturing process, proteins become biologically inactive. Further, denatured proteins can exhibit a wide range of characteristics, including loss of biological function, loss of solubility and/or aggregation.
- The term “refolding” or “renaturating” or “renaturation” refers to a process by which the protein structure assumes its native functional fold or conformation. Due to renaturation or refolding processes, the protein becomes biologically active.
- The term “recombinant” refers to the cloning of DNA into vectors for the expression of the protein encoded by the DNA in a suitable host. The host is preferably a prokaryote, most preferably a bacterium. A “recombinant expression” as used herein refers to expression of proNGF or the proNGF mutein in in prokaryotic host cells, for example E. coli strains suitable for expression of recombinant proteins could be used.
- The term “soluble” refers to a protein which is susceptible of being dissolved in some solvent.
- The term “insoluble” refers to a protein which is not susceptible of being dissolved in some solvent.
- ProNGF Mutants of the Invention
- In a first embodiment of the invention, the present invention provides a proNGF mutant wherein the protease cleavage site R1SK3R4 is substituted at least at positions R1 and K3 corresponding to
positions 101 and 103 of the human wildtype proNGF sequence (SEQ ID NO: 1) by an amino acid selected from non-basic amino acids and Histidine. In other words, at least Arginine R1 atposition 101 and the Lysine K3 at position 103 of the native protease cleavage site R1SK3R4 atpositions 101 to 104 of the human wild type proNGF sequence (SEQ ID NO: 1) are substituted by any amino acid but not Arginine or Lysine. - In the human wildtype proNGF (SEQ ID NO: 1), the native protease cleavage side refers to
amino acids positions 101 to 104 (ArgSerLysArg, RSKR, SEQ ID NO: 9). Amino acid Lysine K3 in position 103 of the wild-type proNGF sequence and amino acid Arginine R1 inposition 101 are replaced with any amino acid but not Arg or Lys to result in a proNGF with improved properties in particular for producing beta-NGF. In order to achieve the above-identified object, i.e. to generate a mutein with improved features for producing beta-NGF, Arginine (R1) or Lysine (K3) may be substituted by all naturally occurring amino acids, or artificial amino acids as well, provided they do not constitute a cleavage site for trypsin. - According to the invention, the amino acid modifications to one or more positions corresponding to residues 101-103 may be substitutions that replace basic amino acids with non-basic amino acids. Theses substitutions can be used to create proNGF mutants according to the invention, in particular, for the production of beta-NGF. Mutants comprise substitutions at least at positions Arg101 and Lys103. The amino acid residues are replaced by a non-basic amino acid or Histidine. Particularly, the mutants of the invention have the substitutions Arg101Val and Lys103Ala. For example, said natural non-basic amino acids may be selected from the group consisting of the naturally occurring amino acid residues Alanine, Asparagine, Aspartic Acid, Cysteine, Glutamine, Glutamic Acid, Glycine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serine, Threonine, Tryptophan, Tyrosine, Valine.
- Amino acids for substitutions at
positions 101 and 103 are not selected from basic (positively charged) amino acids Arginine (Arg) and Lysine (Lys). Also less preferred are amino acids Isoleucine (Ile), Leucine (Leu), or Phenylalanine (Phe), Cysteine (Cys), Proline (Pro) or Tryptophan (Trp). Serine (Ser) is naturally occurring in position 102 of the human proNGF wild-type sequence. X in position 102 (SEQ ID NO: 7 and SEQ ID NO: 8) is preferably selected from Serine (Ser) which is naturally occurring in position 102 of the human proNGF sequence, but may also be selected from any other amino acid wherein the amino acid must be a non-basic amino acid (i.e. not Arginine or Lysine). It is important that the amino acid in position 102 is a non-basic amino acid (i.e. not Arg or Lys). - The amino acid in position 104 of the wild-type human proNGF sequence is preferably Arginine (Arg) which is naturally occurring in position 104 of the human proNGF sequence, but may also be substituted by any other amino acid, preferably a basic amino acid, more preferably Lysine, which allows processing of the proNGF by proteolytic cleavage to obtain beta NGF.
- For example, the presence of Alanine in position 104 of wild-type human proNGF avoids processing of proNGF to beta NGF. Thus, Ala in position 104 is excluded.
- Table 2 summarizes the preferred substitutions for the protease cleavage site of proNGF.
-
Table 2A Preferred amino acids in positions 101-104 of wild-type proNGF The star (*) shows the naturally occurring amino acid in the protease cleavage site (wild-type proNGF, SEQ ID NO: 1). 101 Val, Ala, Asn, Asp, Glu, Gln, Gly, Ser, Thr, Tyr, Met, His, Cys, Pro, Phe, Trp, Ile, Leu 102 Ser*, Gly, Asp, Tyr, Thr, Asn, Glu, Ala, Val, Gln, His, Met, Cys, Pro, Phe, Trp, Ile, Leu 103 Ala, Val, Asp, Asn, Glu, Gln, Gly, Ser, Thr, Tyr, Met, His, Cys, Pro, Phe, Trp, Ile, Leu 104 Arg*, Lys Amino acids Cys, Pro, Phe, Trp, Ile and Leu are less preferred substitutions at Positions 101,102, and 103. Table 2B Most preferred amino acids in positions 101-104 of wild- type proNGF 101 Val, Ala, Gly, Ser, Thr, Asn, Asp, Glu, Gln, Tyr, Met, His 102 Ser*, Val, Ala, Gly, Thr, Asn, Asp, Glu, Gln, Tyr, Met, His 103 Ala, Val, Gly, Ser, Thr, Asn, Asp, Glu, Gln, Tyr, Met, His 104 Arg*, Lys - It is essential that there are any amino acid but not Arg or Lys at
positions 101, 102, and 103 of the proNGF-mutein and that there is a basic amino acid (Arg or Lys) at position 104 of the proNGF-mutein. It was surprisingly shown that specifically two amino acid replacements inpositions 101 and 103 result in high efficiencies of beta-NGF production. - In the sequence of the most preferred proNGF mutant of the invention (SEQ ID NO: 5), the preferred substituted amino acid in
position 101 of human wild-type proNGF is Valine, in position 103 of human wild-type proNGF is Alanine, in position 102 of human wild-type proNGF Serine, and in position 104 of human wild-type proNGF Arginine. In particularly preferred embodiment of the invention, the proNGF mutant of the invention presents has a sequence corresponding to that of SEQ ID NO: 5. - The present invention is also directed to nucleic acids coding for the proNGF mutants described herein as well.
- Method of preparing a human beta-NGF from a proNGF mutant of the invention In a second aspect, the present invention is directed to a method of preparing a biologically active human beta-NGF from an inactive insoluble proNGF mutant substituted at the native protease cleavage site R1SK3R4(SEQ ID NO: 9) at
positions 101 and 103 (R1 and K3) of the human wildtype proNGF sequence (SEQ ID NO: 1), comprising providing a proNGF mutant substituted at the native protease cleavage site R1SK3R4 atpositions 101 and 103 (R1 and K3) of the human wildtype proNGF sequence, and cleaving the proNGF mutant in order to obtain active human beta-NGF. - Preferably, the proNGF mutant is obtained by recombinant expression in prokaryotic cells. Suitable bacterial strains are well known in the art, e.g., E. coli, Bacillus sp., and Salmonella, and kits for such expression systems are commercially available. The preferred host cells for recombinant expression are E. coli, for example E. coli BL21, JM 108/109 (K12), JM106, JM83 and TB1 or derivatives thereof. Any other E. coli strain suitable for expression of recombinant proteins could be used.
- Polynucleotides are operatively linked to expression control sequences allowing expression of the fusion proteins of the invention in prokaryotic host cells. Such expression control sequences include but are not limited to inducible and non-inducible promoters, operators, repressors and other elements that are known to those skilled in the art and that drive or otherwise regulate gene expression. Such regulatory elements include as for example T7, TAC, PBAD, LAC promoters, Lad, LacIQ repressors.
- The sequence of the proNGF mutant is introduced into the prokaryotic host cell by a suitable vector. Suitable Vectors could be for example but not limited to: pBR322, pMAL, pUC19 and all derivatives. The prokaryotic host cell includes but is not limited to prokaryotic cells such as bacteria (for example, E. coli or B. subtilis), which can be transformed with, for example, plasmid DNA, recombinant bacteriophage DNA, or cosmid DNA expression vectors containing the polynucleotide molecules of the invention. In one embodiment of the invention, plasmid vectors are use. For example, but by no way limited to, plasmid vectors described in EP1697523B1 may be used (which is incorporated by reference herein).
- In order to express proNGF muteins, an expression vector is used that contains
-
- a. a strong promoter to direct transcription (e.g. a tac or T7 promoter),
- b. a coding sequence for proNGF or proNGF mutein
- c. a transcription/translation terminator (e.g. t0-terminator of the bacteriophage lambda)
- d. a first selectable marker gene, e.g. a gene coding for antibiotic resistance (e.g. Kanamycin resistence, kan),
- e. a second selectable marker gene, e.g. a gene coding for proB and/or proA.
- f. a repressor gene (e.g. a lad gene)
- g. a high copy number origin of replication
- In one embodiment of the invention, proprietary expression vectors (Scil Proteins GmbH, see EP1697523B1 for the structure of a suitable expression vector) or commercially available vectors may be used for cloning. Regarding general information on the vectors which might be used in the method of the present invention, it is referred to the above mentioned details. However, any suitable vectors might be used as known in the art.
- The structure of the proprietary expression vector pSCIL101 as one example for a suitable vector for the transformation of prokaryotic host cells is depicted below:
- The method of the preparation of a proNGF mutant is comprising the following initial steps:
-
- i. preparing a nucleic acid encoding a proNGF mutein
- ii. introducing said nucleic acid into a procaryotic expression vector;
- iii. introducing said expression vector into a host cell;
- iv. cultivating the host cell;
- v. subjecting the host cell to suitable culturing conditions.
- Due to its expression in prokaryotic host cells, the proNGF mutein is in the form of its inactive, insoluble form.
- In a preferred embodiment, the method of production of beta-NGF from a proNGF mutant according to the present invention comprises the steps of:
-
- a. dissolving the proNGF mutant substituted at the native protease cleavage site R1SK3R4 at positions R1 and K3 corresponding to positons 101 and 103 of the human wildtype proNGF sequence (SEQ ID NO: 1) by solubilisation of inclusion bodies in a denaturating solution;
- b. transferring the proNGF mutant into a refolding solution where the denatured proNGF assumes a biologically active conformation;
- c. purifying the proNGF mutant from the refolding solution;
- d. cleaving the pro-sequence of the proNGF mutant to obtain the active beta-NGF.
- In the following, the preferred steps of a method for producing beta-NGF from a proNGF mutant according to the present invention are discussed.
- Step a: Solubilisation of proNGF Mutant
- Step a) corresponds to dissolving the proNGF mutant substituted at the native protease cleavage site R1SK3R4 at positions R1 and K3 corresponding to positons 101 and 103 of the human wildtype proNGF sequence (SEQ ID NO: 1) by solubilisation of inclusion bodies in a denaturating solution. It is noted that the proNGF mutant of the invention in step a) usually is in the form of its inactive, insoluble form due to its expression in prokaryotic host cells. Inactive proNGF showing a poor solubility is formed during overexpression of the protein in the cytosol of prokaryotes. In this case, proNGF prepared by recombination remains in the cytoplasm in an insoluble and aggregated form. These protein aggregates, the isolation thereof as well as their purification are described for example in Marston, F. A., Biochem. J. 240 (1986).
- To isolate these inactive protein aggregates (inclusion bodies), the prokaryotic cells are disrupted following fermentation. Cell disruption may be performed by conventional methods, e.g. by means of high pressure homogenization, sonification or lysozyme (Rudolph, R., et al. (1997); Folding proteins. In: Creighton, T. E. (ed.): Protein Function: A Practical Approach. Oxford University Press, pp. 57-99).
- Further, the inclusion bodies are solubilized. Inclusion bodies (TB) are accumulations of usually defective or incompletely folded proteins. They form inside cells, for example bacteria cells, such as E. coli, in the event of excessive expression of recombinant proteins. The inclusion bodies employed according to the invention preferably comprise the proNGF mutein. This means that they contain at least 60, at least 70, at least 80 or at least 90 wt. % of pro-NGF (based on the total amount of protein).
- The invention provides a method for the production of proNGF mutein thereof, wherein inclusion bodies which non-folded, inactive, insoluble proNGF mutein or a derivative thereof are solubilized in a denaturing buffer (solution).
- The denaturating solution of step a) preferably comprises a solution containing (i) a chaotropic agent, (ii) a chelator, (iii) a buffer, and (iv) a reducing agent.
- The denaturation buffer comprises at least one chaotropic substance (agent). Chemical substances which dissolve ordered hydrogen bridge bonds in water are called chaotropic. Since the hydrogen bridge bonds are broken open, the chaotropic substances interfere with the water structure and ensure disorder (increase in entropy). The reason for this is that the formation of the H2O cage structures necessary for the solvation is prevented. In the case of amino acids, they reduce the hydrophobic effects and have a denaturing action on proteins, since a driving force of protein folding is the assembling together of hydrophobic amino acids in water. Generally, any substance which exerts the hydrophobic effect in the solubilization buffer and therefore has a denaturing action on the proteins can be employed as a chaotropic substance. Chaotropic substances are in general salts or low molecular weight compounds, such as urea. Chaotropic substances are clearly distinguished from detergents, since they contain no hydrophobic radical, such as an alkyl radical, in the molecule. Generally, the chaotropic action is accompanied by an improvement in the solubility of the protein, in this case the prethrombin.
- In a preferred embodiment of the invention, the chaotropic compound is chosen from guanidinium salts, in particular guanidinium hydrochloride and guanidinium thiocyanate, iodides, barium salts, thiocyanates, urea and perchlorates.
- The chaotropic compounds are employed in conventional amounts. For example, 4-8 M guanidinium hydrochloride or 4-9 M urea can be employed.
- The denaturation buffer comprises a reducing agent compound, for example a disulphide compound such as Glutathione (GSH). The disulphide compound is capable of forming mixed disulphides with thiol groups (—SH) of cysteines of the polypeptides in the inclusion bodies. The disulphide is added to the solution. The disulphide does not designate proteins which the inclusion bodies comprise and which possibly comprise disulphide bridges. Preferably, the disulphide is not a true peptide. Preferably, the disulphide is a low molecular weight compound. The molecular weight is, for example, lower than 2,000 g/mol or than 1,000 g/mol. The disulphide is employed, for example, in a concentration of from 5 mM to 1 M, in particular 10 mM to 0.5 M.
- In a preferred embodiment of the invention, the disulphide compound is glutathione disulphide. Glutathione (GSH), also γ-L-glutamyl-L-cysteinylglycine, is a pseudo-tripeptide which is formed from the three amino acids glutamic acid, cysteine and glycine. GSH is present in the cytoplasm of both prokaryotes and eukaryotes and is involved in the formation of disulphide bridges. It is in equilibrium with the dimer GSSG, which contains a disulphide bridge. Glutathione reacts with cysteines R—SH and R′—SH from two polypeptides or from a single polypeptide in a disulphide exchange reaction:
-
R—SH+GSSG→R—S—S-G+GSH. - RSSG is called a mixed disulphide. It is reacted with a further cysteine of a polypeptide, so that as a result a disulphide bridge is obtained between two cysteines:
-
R—S—S-G+HS—R′→R—S—S—R′+GSH. - Glutathione is kept enzymatically in the reduced form (GSH) in the cytosol. “Reducing conditions” in the cytosol are therefore referred to. Conditions are established in the solubilization buffer so that the disulphide compound it comprises catalyses the formation of disulphide bridges in accordance with the reactions described above. The GSSG is employed, for example, in a concentration of from 10 mM to 0.5 M.
- Alternatively, as reducing agent (reductant), Cysteine might be used.
- In a preferred embodiment of the invention, the denaturation solution is a Tris buffer.
- The denaturation solution can comprise further conventional additives, for example EDTA or salts. The pH of the solubilization buffer is, for example, between 7 and 10, preferably
pH 8. - The solubilization is preferably assisted mechanically, for example with conventional homogenization apparatuses or by means of ultrasound. After the solubilization, solids which remain are preferably separated off The supernatant comprises the solubilized pro-NGF.
- In one embodiment of the invention, the denaturing solution comprises
-
- i. Guanidinium-HCl, 1-8 M, preferably 4-6 M, most preferred 4 M, GSH or Cysteine, 1-100 mM, preferably 5 mM
- ii. Tris, 0.01-1 M, preferably 0.1 M,
- iii. EDTA, 1-50 mM, preferably 10 mM
- iv. pH 7.0-10.0, preferably pH 8.0
- A concentration of 4 M Guanidinium-HCl is in most cases sufficient for a complete denaturation of proNGF mutein.
- Step b: Refolding of the proNGF Mutant
- After the solubilization of the proNGF mutant from inclusion bodies it is necessary to refold the protein in its native conformation. For the refolding process it is important to minimize the competing reactions misfolding and aggregation. To prevent aggregation the refolding is performed at very low protein concentrations because aggregation of the protein is predominant at high protein concentrations. In step b), transferring the proNGF mutant into a refolding buffer occurs where the denatured proNGF assumes a biologically active conformation. A biologically active conformation can be determined by the presence of disulfide bridges occurring in natural beta-NGF.
- In a preferred embodiment of the invention, the solubilized proNGF mutant is renatured in a refolding solution which contains at least one chaperone, at least one a metal chelator, and a redox shuffling system.
- In a preferred embodiment, the method according to the present invention uses a refolding solution in step b) comprising
-
- i. a chaperone, preferably Arginine, 0.5-1.0 M, preferably 0.75 M,
- ii. a metal chelator, preferably EDTA, 1-10 mM, preferably 5 mM,
- iii. a redox shuffling system, at 0.1-10 mM, preferably 1 mM L-Cystine and 5 mM L-Cysteine, or 1 mM GSSG (oxidized glutathione) and 5 mM GSH (reduced glutathi-one).
- iv. pH 8.0-pH 11.0, preferably pH 9.5
- Alternative redox shuffling systems such as Cystamin/Cysteamin could be used.
- In a preferred embodiment of the invention, the folding assistant is Arginine. Compounds which promote the folding of proteins can generally be employed as “folding assistants”. Such compounds are known to the person skilled in the art. They can assist the folding in various ways. It is assumed that arginine destabilizes incorrectly folded intermediates, so that these are at least partly unfolded again (from a thermodynamic dead-end) and therefore can be correctly folded again. On the other hand, glycerol usually stabilises proteins. Compounds which increase the absolute yield of folded pro-NGF mutein in the method according to the invention by more than 5%, in particular by more than 10% or more than 20% (based on the total amount of pro-NGF employed for the folding), compared with a method without using the folding assistant, are suitable in particular as folding assistants.
- The refolding is preferably carried out at a pH of between 8 and 11, in particular pH 9.5.
- To increase the protein concentration in the refolding vessel, a pulse renaturation was carried out. Limiting for the number of pulses is the Guanidinium-HCl concentration which should not exceed 0.3 M. The protein concentration per pulse should not exceed 50 μg/ml in relation to the final refolding volume.
- In a preferred embodiment of the invention, the solubilisate is added to the folding batch in several fractions or continuously over several days. Preferably, the solubilisate is added in a “pulse renaturing” by rapid dilution to the solubilisate. In this context, for example but by no means limited to, at least 6 pulses could be performed in a time interval of, for example, 24 hours. The number of pulses is set such that after the addition of the solubilization batch the concentration of protein which has not yet been folded is not too high, since otherwise aggregates are obtained. For example, with each pulse 0.05 g/l to 0.2 g/l, preferably 0.1 g/l of protein is newly transferred into the folding batch (based on the protein concentration in the folding batch after addition of the solubilisate). For example, each refolding step takes at least 1-2 h.
- After refolding, the refolding reaction needs to be clarified before loading onto a column. This can be done by any methods known in the art, for example, by filtration.
- In a preferred embodiment, the method for producing a correctly folded pro-NGF mutant includes the following steps: a) Inclusion bodies which comprise insoluble proNGF mutant are solubilized in a denaturing solution as described above, and b) the solubilized pro-NGF is then renatured in a refolding solution buffer as described above.
- In a preferred embodiment of the invention, the denaturing solution and/or the refolding solution consequently contains no detergent. It has been found, that the use of detergents is not necessary for the solubilization and/or folding of pro-NGF mutein. This is advantageous, since certain detergents are comparatively aggressive chemical substances which pharmaceutical products should not comprise or should comprise in only small amounts and therefore must be removed in an expensive manner. The method according to the invention is therefore advantageous compared with the method of Soejima et al., 2001, in which such aggressive detergents (Triton X-100 or Brij-58) are employed for folding the protein. In other words, no detergents are used in the entire production method according to the invention, and the production method is therefore detergent-free.
- Step c: Purification of proNGF Mutant by Chromatography
- By carrying out the method according to the invention with the denaturation and subsequent refolding, an aqueous solution of folded pro-NGF mutein is obtained. The folded pro-NGF mutein can subsequently be purified further by known methods.
- In a preferred embodiment the proNGF mutant is purified from the refolding (e.g. non- or weak denaturing) solution via chromatographic purification, in particular by means of a mixed mode chromatography (step c of the method of production of beta NGF from a proNGF mutant of the invention). The most preferred column for the chromatography is a column with a synthetic affinity ligand, preferably 4-mercapto-ethyl-pyridine (MEP Hypercell; Pall). Advantages of this medium are that the binding is independent of the ionic strength, salt stacking is not necessary and higher flow rates to fasten the process are possible. Further, the elution is done by a pH-shift.
- Other mixed mode material columns are known and could be used. For example, but not limited to, MEP (Pall; affinity ligand is 4-Mercapto ethyl pyridine), HEA (Pall; affinity ligand: Hexylamino), PPA (Pall, affinity ligand: Phenylpropylamino), MBI (Pall; affinity ligand: 2-Mercapto-5benzamidazole sulfo acid), Capto MMC (GEHC), Capto adhere (GEHC; affinity ligand: N-benzyl-N-methyl ethanolamine), CHT hydroxyapatite (BioRad), CHT fluoroapatide). The MEP, HEA, PPA, and MBI columns have a hydrophobic binding, where Capto MMC is a cation exchanger with mixed mode functionality and Capto adhere is an anion exchanger with mixed mode functionality. The BioRad columns are ion exchange columns with hydrophobic components. Any other mixed mode material column not listed here could also be used to purify the proNGF mutant.
- Step d: Cleavage of proNGF to Beta-NGF
- proNGF is the precursor of beta-NGF. Thus, in step d) of the method of production of beta-NGF from a proNGF mutant of the invention, the pro-sequence of the proNGF mutant is cleaved in order to obtain an active beta-NGF.
- Proteases having trypsin-like substrate specificity cleave the protein without digesting the active portion of the protein molecule. Trypsin-like proteases cleave peptide bonds following a positively charged amino acid such as Arginine or Lysine. As trypsin-like proteases, several serine proteases (serine endopeptidases) are considered for processing of the proNGF to result beta-NGF. Preferably, the serine protease Trypsin is used for the cleavage of the pro-sequence but other proteases could be used instead.
- It is noted that cleavage is not restricted to trypsin itself, but may involve other proteases having trypsin-like substrates as well. Generally, if the ratio of proNGF to trypsin (or other protease) is appropriately adjusted, the correctly folded, mature beta-NGF will not be cleaved by this protease. In contrast, denatured proteins as well as folding intermediates expose sequences which are susceptible to an attack by the protease.
- Preferably for the cleavage of proNGF mutant to beta-NGF, the ratio of trypsin (or other protease) to proNGF mutant is from 1:200-1:100.000, more preferably from 1:5.000-1:20.000 per weight, most preferred is a ratio of 1:10.000 (w/w). In a most preferred embodiment, the cleavage occurs for 8-23 hours at room temperature, most preferred 18 hours. Under the conditions used in this invention, proNGF mutant is cleaved completely and almost no by-products are formed. No aggregation was observed.
- As clearly described in the Examples, the present inventors have found that the amino acid modifications introduced in the proNGF mutant of the invention not only avoid cleavage of the protein at undesired cleavage sites but also unexpectedly result in a great increase in the efficiency of the cleavage of Trypsin compared to that of the wild type proNGF, which allows to carry out the cleavage under very selective conditions to obtain a very pure product.
- In details, the experimental data clearly show that at already a very low Trypsin/Protein ratio such as 1:100.000, the proNGF mutant of the invention (SEQ ID NO: 5) results in very high purity recombinant human beta-NGF with a high cleavage yield (about 85%). Furthermore, wild type proNGF (SEQ ID NO: 1) at the same Trypsin/Protein ratio shows a low cleavage yield (about 5%). A satisfactory yield is only obtained at much higher trypsin/protein ratios (1/250), but this is accompanied by low selectivity and a high product degradation due to overdigestion.
- Step e: Further Purification of Beta-NGF
- The beta-NGF produced from a proNGF mutant of the invention is further purified, for example, by several chromatographic methods. Further purification steps are required to separate Trypsin and product related impurities of the tryptic digestion from beta-NGF. Purification steps should reduce HCPs, Endotoxins, and DNA. Any methods known in the art for protein purification can be used. Most preferred are chromatographic purifications, for example with Sepharose columns (e.g. SP Sepharose HP, Q Sepharose FF).
- The final product beta-NGF produced from a proNGF was analyzed regarding its purity by SDS-PAGE, rp-HPLC, SE-HPLC, and IEX-HPLC. HPLC analyses revealed a purity of beta-NGF of at least 97%.
- In a preferred embodiment of the invention, the method for the production of a pro-NGF mutein suitable for obtaining beta-NGF includes the following steps:
-
- a) expression of a recombinant pro-NGF mutant with substituted protease cleavage site in prokaryotic cells
- b) isolation of the pro-NGF mutein-containing inclusion bodies,
- c) mixing of the inclusion bodies with a suitable denaturing buffer comprising at least (i) a chaotropic substance, (ii) a chelator, (iii) a buffer, and (iv) a reducing agent
- d) refolding in a refolding solution comprising at least a chaperone, a metal chelator, and a redox shuffling system,
- e) purification of the refolded pro-NGF mutant,
- f) cleavage into the active form of beta-NGF with proteases such as trypsin
- g) isolation and purification of the beta-NGF.
- Use of proNGF for the Production of Beta-NG
- In a third aspect, the invention is directed to the use of the proNGF mutant of the present invention for producing human beta-NGF.
- Pharmaceutical Composition of betaNGF Obtained from proNGF Mutants of the Invention
- In a further aspect, the invention is directed to a pharmaceutical composition comprising betaNGF obtained from a proNGF-mutant being substituted at the native protease cleavage site R1SK3R4 at
positions 101 and 103 (K3 and R1) of the human wildtype proNGF sequence (SEQ ID NO: 1) as described above and a pharmaceutically acceptable carrier. - In one embodiment of the invention, the pharmaceutically active beta-NGF is administered to the patient by gene-therapeutical methods. In gene therapy, there are two basic methods available, suitable for introducing a gene, in the present case a gene coding for a beta-NGF, into the patient.
- In the ex vivo application, the pharmaceutically active gene encoding beta-NGF is introduced in a body cell by a vector, where the body cell preferably is a glial cell, and the cell treated in this way then is re-introduced into the patient, for example by micro- or nanoparticles. Particularly preferred is a specific integration of the beta-NGF gene in the cellular genome.
- In the in vivo-gene therapy, the beta-NGF gene is transported to target cells in the body by vectors, for example by means of viruses, which on the one hand may infect the target cell und, thus, will be able to introduce the pharmaceutically active beta-NGF gene, but, on the other hand, are not able to reproduce themselves within the target cell. In this approach, nano- or microparticles, for example liposomes, which may fuse with the cell membrane, may be used a vectors as well.
- As a vector for the beta-NGF gene, a virus or an antibody might be used as an example, capable of specifically infecting the host cell or which immunoreacts with an antigen in the target cell. As a viral vehicle, retroviruses might be used as an example. Furthermore, it is possible to use adenoviruses or Vaccinia based vectors, for example, modified vaccinia virus Ankara (MVA).
- The skilled person will be able to select a suitable formulation based on routine considerations and will chose a suitable form for administering the present pharmaceutical composition to a patient. For example, the pharmaceutical composition might comprise one or more pharmaceutically acceptable ingredients, for example carriers or diluents. Among these classes of substances, one might name fillers, salts, buffers, stabilisators, penetration enhancers and other well-known materials. Techniques for the formulation of pharmaceutical compositions of the present invention may be found in well-known standard textbooks such as “Remington's Pharmaceutical Sciences”, Mack Publishing Co., Easton, Pa., latest edition.
- The dosage of the betaNGF obtained by the method of production as described in the present invention might be in a range of 0.1 μg/kg to 500 μg/kg body weight, if administered by infusion, and from 2 μg/kg to 2 mg/kg body weight if administered by injection.
-
FIG. 1 shows the sequence of pro-NGF and of the pro-NGF mutants of the invention. Shown in bold letters is the sequence of the proform of human beta-NGF. Shown in bold and underlined is the protease (trypsin) cleavage site (amino acids 101-104 of SEQ ID NO: 1; trypsin cleavage sites are between amino acids 101-102 (R1), 103-104 (K3) and 104-105 (R4)). X in the sequence can be any amino acid. -
FIG. 1a shows a sequence of human proNGF (SEQ ID NO: 1) with protease cleavage site RSKR (SEQ ID NO: 9). -
FIG. 1b shows a sequence of a proNGF mutant of the invention (SEQ ID NO: 2) with the protease cleavage site VSXR (SEQ ID NO: 10). -
FIG. 1c shows a sequence of a proNGF mutant of the invention (SEQ ID NO: 3) with the protease cleavage site mutated to XSXR (SEQ ID NO: 11). -
FIG. 1d shows a sequence of a proNGF mutant of the invention (SEQ ID NO: 4) with the protease cleavage site mutated to XSAR (SEQ ID NO: 12). -
FIG. 1e shows a sequence of a proNGF mutant of the invention (SEQ ID NO: 5) with the protease cleavage site mutated to VSAR (SEQ ID NO: 13). -
FIG. 1f shows a sequence of a proNGF mutant of the invention (SEQ ID NO: 7) with the protease cleavage site mutated to XXXR (SEQ ID NO: 14). -
FIG. 1g shows a sequence of a proNGF mutant of the invention (SEQ ID NO: 8) with the protease cleavage site mutated to VXAR (SEQ ID NO: 15). -
FIG. 1h shows sequences of protease cleaving sites (SEQ ID NO:s 6, 9-15). -
FIG. 2 . Processing of proNGF or pro NGF mutants to beta-NGF -
FIG. 2a shows six beta NGF cleavage products after trypsin cleavage by using the wild type proNGF having a native furin cleavage site RSKR. The drawing clearly shows that a cleavage of wild type proNGF to betaNGF results in an inhomogenous mixture of many different cleavage products. -
FIG. 2b shows native beta NGF cleavage products after trypsin cleavage by using a proNGF mutant SP174-101 (SEQ ID NO: 5) with deletion of the native furin cleavage site. The protease cleavage site RSKR (SEQ ID NO: 9) was substituted by two amino acids to result a site VSAR (SEQ ID NO: 12). This site can only be cleaved by a protease after the amino acid Arginine in position 104; Trypsin can only cleave at one cleavage site (instead of three). The drawing clearly shows that a cleavage of mutant proNGF SP174-101 (SEQ ID NO: 5) to beta-NGF results in only one homogenous cleavage product (beta-NGF). -
FIG. 3 shows the refolding of the proNGF mutant SP174-101 (SEQ ID NO: 5) compared to wild type proNGF. The figure compares the refolding yield of the wild type proNGF (continuous line) and the proNGF mutant (broken line) with the protease cleavage site mutated to VSAR. It can be clearly seen from the figure that the refolding efficiency of wild type and mutant proNGF is identical. -
FIG. 4 shows the purification of a proNGF mutant SP174-101 with the protease cleavage site mutated to VSAR (SEQ ID NO: 5) by a MEP HyperCel column. The figure shows an elution profile of MEP HyperCel purification of a refolded and filtrated proNGF mutant. -
FIG. 5 shows the cleavage of a proNGF mutant SP174-101 with the protease cleavage site mutated to VSAR (SEQ ID NO: 5) by Trypsin. The figure shows a Coomassie stained SDS-PAGE gel of fractions of the tryptic cleavage. The tryptic cleavage product of the proNGF mutant can be seen in lanes 4-7. The figures clearly show that the purified proNGF mutant results in only one cleavage product (beta-NGF). -
FIG. 6 shows the purification of beta-NGF. The figure shows a profile of a SP Sepharose HP column after the tryptic cleavage. The tryptic digestion reaction was loaded onto a SP Sepharose HP column. The elution was done in three steps (a. 25% 25 mM sodium phosphate, 1 M NaCl, pH 6.5 (buffer B), b. in a linear gradient from 25-50% buffer B, and c. 100% buffer B (flow rate 60 cm/h)). -
FIG. 7 shows the structure of the proprietary expression vector pSCIL1101. - The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the methods and compositions of the invention, and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers used but some experimental errors and deviations should be accounted for. Unless indicated otherwise, molecular weight is average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.
- Substitution of Arginine R1 and Lysine K3 corresponding to
positions 101 and 103 of human pro-NGF (SEQ ID NO: 1) was realized on DNA level using a synthesized gene by methods as known to someone skilled in the art. Serine in position 102 either remained unchanged or substitution of position 102 of human pro-NGF (SEQ ID NO: 1) was also realized on DNA level using a synthesized gene by methods as known to someone skilled in the art. Lysine K4 corresponding to position 104 was not substituted. Sequences are shown inFIG. 1 . - The bacterial host E. coli JM108 used for expression of rh-proNGF (DSMZ 5585; F thi Δ (lac-proAB) end AI gyrA 96 relA1 phx hsdR17 supE44 recA) is proline-auxotrophic, which was neutralized by the use of the plasmid with the designation pSCIL101. The plasmid pSCIL101 is based on the plasmid pSCIL008 (see WO05061716). The strain cannot synthezise thiamine (Vieira & Messing, 1982 Gene. Oct; 19(3): 259-68). The pro-NGF mutant shown in SEQ ID NO: 5 is expressed under the control of the tac promoter located on pSCIL101. The vector pSCIL101 used here is a high copy plasmid with a kanamycin resistance. The expression is carried out in defined mineral salt medium and is induced by the addition of IPTG. The pro-NGF mutant is deposited in the cytosol in the form of inclusion bodies (IBs).
- Cell Line:
-
- host strain, e.g. E. coli HMS174 (K12) or JM108 (K12)
- proNGF mutant SP174-101 (SEQ ID NO: 5)
- Tac promoter (IPTG induction)
- ColE1 replicon
- Kanamycin resistance
- proBA selection
- Proprietary vector system pSCIL 101 (e.g. see WO051061716)
- The aim of this fermentation was to obtain product and biomass for subsequent process steps. To monitor the over-expression of the target protein during the fermentation process, samples were analyzed by means of SDS-PAGE before and after induction.
-
- Mineral salt medium without antibiotics
- Batch phase μ≈0.25 h−1 (ODend=18)
- Fed batch phase I exponential feeding with μset=0.18 h−1
- Fed batch phase II: constant feed rate
- Point of induction ODind=60±5
- 1.0 mM IPTG
- Time of induction 5 h
- Final OD=82±4
- Process time 28.5 h±1.25
-
Plasmid Stability 100% - Yield: 40 mg/g proNGF; 1.2 g/L±0.2 g/L proNGF
- In bacterial cells, the recombinant protein is present in the form of aggregates. The expression of the pro-NGF mutein took place in the form of IBs. The cell breakdown and the IB preparation were carried out in accordance with standard protocols and can be conducted on the laboratory scale up to a working up of approx. 200 g of biomass. The preparation of these “inclusion bodies” containing the proNGF mutein was performed according to Rudolph, R., et al. (1987); Folding proteins. In: Creighton, T. E. (ed.): Protein Function: A Practical Approach. Oxford University Press, pp. 57-99, and according to EP0994188B1. For cell disruption, the cell pellets were resuspended in a suitable buffer and subsequently the cells were disrupted using high pressure homogenization in 50 mM Natriumphosphat pH 7.0, 1 mM EDTA.
- The inclusion bodies were solubilized in a denaturing solution which comprised a solution (i) a chaotropic agent, (ii) a chelator, (iii) a buffer, and (iv) a reducing agent. For solubilization, Guanidinium HCl (GuaHCl) was tested in a concentration range of 4.0-6.0 M. The solubilization buffer was mixed in different ratios with a inclusion-body slurry (IB slurry). All experiments had a final Cysteine concentration of 5 mM and were carried out at room temperature. Results were analyzed by SDS-PAGE (data not shown). The experiments revealed that a concentration of 4 M GuaHCL was sufficient for complete solubilization of inclusion bodies. The ratio of inclusion body-slurry to buffer is 1+1.25 (v/v) (IB slurry:buffer). The final conditions of the denaturing solution for solubilization of inclusion bodies were:
-
- i. 4 M Guanidinium-HCl,
- ii. 0.1 M Tris,
- iii. 10 mM EDTA
- iv. 5 mM Cysteine
- v. pH 8.0
- The solubilisate is clarified by depth filtration according to standard procedures.
- The protein concentration was then determined using the method of Bradford (Bradford, M. M., Anal. Biochem. 72 (1976) 248). The protein concentration of proNGF mutein was between 10-20 mg/ml.
- After solubilization, it is necessary to refold the protein in its native conformation and thereby minimize misfolding and aggregation. To prepare biologically active proNGF mutein according to the invention from solubilized materials, these were diluted into a refolding solution wherein proNGF assumes a biologically active conformation.
- The final refolding solution for the solubilizate based on IB-slurry comprised
-
- i. 0.75 M Arginine
- ii. 5 mM EDTA
- iii. 1 mM L-Cystine and 5 mM L-Cysteine
- iv. pH 9.5
- The obtainment of NGF in the active conformation was confirmed by the presence of the disulfide bridges occurring in mature human beta-NGF.
- To increase protein concentration in the refolding process, a pulse renaturation was carried out. A pulse was given every hour per 50 μg/ml proNGF mutant protein. The concentration of Guanidinium-HCl in the solution should not exceed 0.3 M. In order to achieve this, 15 pulses were required. The clarified refolded fraction was filtered before loading to further columns.
- The performance of the refolding reaction was analysed after every pulse by rp-HPLC. The resulting peak area was blotted against the number of pulses. For the rp-HPLC, a reversed-phase column (e.g., 214MS54, 4.6×250 mm; 300 Å, 5 μm, Vydac) with guard column (e.g. 214GK54; 300 Å; Vydac) was used. The running buffers were H2O with 0.05% trifluoroacetic acid (TFA) and Acetonitrile with 0.05% TFA. The flow rate was 1 mL/min. Results are shown in
FIG. 3 . It can be seen fromFIG. 3 that the refolding efficiency of wild type and mutant proNGF is identical. - A column with a synthetic affinity ligand, 4-mercapto-ethyl-pyridine (MEP) was used. The elution was done by shifting the pH-value. Further, elution was carried out with a low salt concentration which is beneficial for an efficient process design.
- The column was equilibrated with 0.75 M Arginine, 5 mM EDTA, pH 9.5. The clarified refolding reaction was loaded onto MEP HyperCel column (Pall) with a maximal loading capacity of 5 g proNGF mutant per L column media. In the washing step, most impurities and unbound protein were depleted by using buffer 2 M GuaHCl, 0.1 M Tris-HCl, pH 8.0 and 10 mM Tris-HCl, pH 8.0. The elution was done in a linear gradient from 0-70% 50 mM Acetate, pH 4.0 (flow rate 120 cm/h).
FIG. 4 shows an elution profile of MEP HyperCel purification of a refolded and filtrated proNGF mutant with the protease cleavage site mutated to VSAR (SEQ ID NO: 5) of the invention. At the GuaHCL washing step “many impurities were removed. At “pool”, about 60-70% of the proNGF mutant was recovered. - For the tryptic digestion of proNGF mutant to beta-NGF, such a Phosphatebuffer was used, which do not inhibit the activity of the protease. Sodium phosphate buffer was added to the MEP-eluate to a final concentration of 25 mM sodium phosphate. The pH-value was adjusted to pH 6.5. For proteolysis, Trypsin (Roche, GMP grade) was added in a ratio of 1:10,000 (w/w) (trypsin:proNGF). The proteolysis was carried out using an incubation time of 18 h at room temperature. Performance and yield of the tryptic digestion were analyzed by SDS-PAGE, rp-HPLC and UV/VIS280nm.
FIG. 5 shows an SDS-PAGE of fractions of the tryptic cleavage. A 4-12% Bis/Tris-Gel, 1 mm, 1×MES as running buffer (Invitrogen) was used. Lanes 5-7 show the tryptic cleavage products compared to the uncleaved proNGF mutant (rhproNGF*, see lane 3) and to the mature beta-NGF (NGF; see lane 8). The figures clearly show that the purified proNGF mutant results in only one cleavage product (beta-NGF). A complete digestion of proNGF mutant to beta-NGF could be observed. - After the tryptic digestion, beta-NGF was loaded onto a SP Sepharose HP column to deplete Trypsin, by-products of the cleavage and further impurities. The SP Sepharose HP purification is shown in
FIG. 6 . - The column was equilibrated with 25 mM Na-phosphate buffer (pH 6.5). The tryptic digestion reaction was loaded onto a SP Sepharose HP column (2 g beta-NGF/L medium) and unbound protein washed with the equilibration buffer. The elution was done in three steps (3 cv 25% 25 mM Na-phosphate pH 6.5/1 M NaCl (buffer B), 10 cv in a linear gradient from 25-50% buffer B, and 3
cv 100% buffer B (flow rate 60 cm/h)). -
FIG. 6 shows the purification of beta-NGF. The figure shows a profile of a SP Sepharose HP column after the tryptic cleavage. The yield of beta-NGF was 85-95% (peak “sample elution”). - This procedure was applied in parallel for both proNGF-mutant SP174-101 (SEQ ID NO: 5) and human wild-type proNGF (SEQ ID NO: 1; rhProNGF).
- 5 mL of purified rhProNGF were dialyzed against 25 mM phosphate buffer pH 6.5. Following dialysis, a protein concentration of 0.08 mg/mL was measured by HPLC-UV. Per digestion sample, 80 lμg of proNGF were employed. After proteolysis, all samples were analyzed by HPLC-UV.
-
Mass ratio 1/10.000 w/w of trypsin/rhProNGF mutant was used, while different mass ratios of trypsin/rhProNGF wild type were used (see Table 3). As per trypsin solution 1.0 μg/mL and 10 μg/mL were used. After an overnight incubation (about 17 hours) at room temperature, all samples were analysed. For control porpoises rhProNGF mutant without added protease was also incubated. -
TABLE 3 Trypsin/ Trypsin Trypsin rhProNGF rhProNGF rhProNGF Volume Amount rhProNGF Volume Amount ratio (μL) (μg) Type (μL) (μg) Control — Mutant 1000 80 1/10000 8 (1 μg/mL) 0.008 Mutant 1000 80 1/10000 8 (1 μg/mL) 0.008 Wild Type 1000 80 1/5000 16 (1 μg/mL) 0.016 Wild Type 1000 80 1/1000 8 (10 μg/mL) 0.08 Wild Type 1000 80 1/250 32 (10 μg/mL) 0.32 Wild Type 1000 80 - Performances and yields of all tryptic digestions were analysed by HPLC-UV using a Vydac 214MS C4 column.
- Table 4 shows the cleavage yields obtained after tryptic digestion. The experimental data clearly show that cleavage of the proNGF mutant SEQ ID NO: 5 with Trypsin results in only one product (beta-NGF) at high cleavage yield (about 85%) using a very low trypsin/protein ratio (1/10.000). This can be compared to the cleavage of the wildtype proNGF (SEQ ID NO: 1) which shows a low cleavage yield (only about 5%) at low trypsin/protein ratio (1/10.000) and a high product degradation (overdigested) at high trypsin/protein ratio (1/250).
-
TABLE 4 % betaNGF Trypsin/ Over- Amount ProNGF % % digested μg ratio ProNGF betaNGF Forms ProNGF Standard 80 — 100 NGF Standard 42 100.0 ProNGF SEQ ID 1/10000 1.9 84.5 NO: 5 80 ProNGF Wild Type 80 1/10000 67.1 4.6 — ProNGF Wild Type 80 1/5000 21.5 18.6 6.6 ProNGF Wild Type 80 1/1000 0.0 77.9 12.9 ProNGF Wild Type 80 1/250 0.0 67.9 25.7 - TF1 cells (ATCC, catalog nr. CRL2003) were cultivated according to standard procedures. A test medium (90
% medium RPMI 1640, 10% foetal bovine serume FBS, 50 U/ml Penicillin und 50 μg/ml Streptomycin) was added to the cells and centrifuged. The pellet was resuspended at a density of 1.5·105 cells/ml in test medium at 37° C. The cell suspension was mixed with different concentrations of proNGF protein (10−M, 3·10−10 M, 10−9 M, 3·10−9 M, 10−8 M, 3·10−8 M, 10−7 M, 3·10−7 M, 10−6 M, 3·10−6 M, 10−5M und 3·10−5 M) and analyzed in 96-well-plates. After incubation for 48 h at 37° C., cell proliferation reagent (e.g. WST-1, Roche Applied Science, cat no. 1644807) was added and the plates again incubated for 4 h at 37° C. The absorption was measured at 450 nm and the EC50-value determined by using suitable programs (z. Bsp. Sigma-Plot 2000).
Claims (24)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/376,969 US20200031893A1 (en) | 2011-12-19 | 2019-04-05 | Novel prongf mutants and uses thereof in the production of beta-ngf |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11194208 | 2011-12-19 | ||
EP11194208.2 | 2011-12-19 | ||
PCT/EP2012/076251 WO2013092776A1 (en) | 2011-12-19 | 2012-12-19 | Novel prongf mutants and uses thereof in the production of beta-ngf |
US201414366460A | 2014-06-18 | 2014-06-18 | |
US14/978,407 US10308694B2 (en) | 2011-12-19 | 2015-12-22 | ProNGF mutants and uses thereof in the production of beta-NGF |
US16/376,969 US20200031893A1 (en) | 2011-12-19 | 2019-04-05 | Novel prongf mutants and uses thereof in the production of beta-ngf |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/978,407 Division US10308694B2 (en) | 2011-12-19 | 2015-12-22 | ProNGF mutants and uses thereof in the production of beta-NGF |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200031893A1 true US20200031893A1 (en) | 2020-01-30 |
Family
ID=47428641
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/366,460 Active 2033-03-10 US9617322B2 (en) | 2011-12-19 | 2012-12-19 | ProNGF mutants and uses thereof in the production of beta-NGF |
US14/978,407 Active US10308694B2 (en) | 2011-12-19 | 2015-12-22 | ProNGF mutants and uses thereof in the production of beta-NGF |
US16/376,969 Pending US20200031893A1 (en) | 2011-12-19 | 2019-04-05 | Novel prongf mutants and uses thereof in the production of beta-ngf |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/366,460 Active 2033-03-10 US9617322B2 (en) | 2011-12-19 | 2012-12-19 | ProNGF mutants and uses thereof in the production of beta-NGF |
US14/978,407 Active US10308694B2 (en) | 2011-12-19 | 2015-12-22 | ProNGF mutants and uses thereof in the production of beta-NGF |
Country Status (28)
Country | Link |
---|---|
US (3) | US9617322B2 (en) |
EP (2) | EP2672984B1 (en) |
JP (4) | JP6039146B2 (en) |
KR (2) | KR20160120788A (en) |
CN (2) | CN104203264B (en) |
AU (1) | AU2012357052B2 (en) |
BR (1) | BR112014014913B1 (en) |
CA (1) | CA2859262C (en) |
CY (2) | CY1117016T1 (en) |
DK (2) | DK2672984T3 (en) |
EA (1) | EA031333B1 (en) |
ES (2) | ES2657344T3 (en) |
HK (1) | HK1202055A1 (en) |
HR (2) | HRP20150900T1 (en) |
HU (2) | HUE036265T2 (en) |
IL (1) | IL233137A0 (en) |
LT (1) | LT2907521T (en) |
MX (2) | MX353074B (en) |
NO (1) | NO2907521T3 (en) |
PL (2) | PL2672984T3 (en) |
PT (2) | PT2672984E (en) |
RS (2) | RS56893B1 (en) |
SG (2) | SG11201402585PA (en) |
SI (2) | SI2672984T1 (en) |
SM (1) | SMT201500201B (en) |
TR (1) | TR201802360T4 (en) |
WO (1) | WO2013092776A1 (en) |
ZA (1) | ZA201403753B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2672984E (en) | 2011-12-19 | 2015-10-01 | Wacker Chemie Ag | Novel prongf mutants and uses thereof in the production of beta-ngf |
US20160220639A1 (en) * | 2013-09-11 | 2016-08-04 | New York University | Methods and compositions for treating bone diseases |
EP3406259A1 (en) | 2017-05-24 | 2018-11-28 | Dompé farmaceutici S.p.A. | Neurotrophins for use in the treatment of hearing loss |
CN108456681B (en) * | 2018-03-26 | 2019-10-11 | 江苏中新医药有限公司 | The assortment of genes of efficiently expressing recombinant human nerve growth factor |
WO2019207106A1 (en) | 2018-04-27 | 2019-10-31 | Chiesi Farmaceutici Spa | Production of nerve growth factor (ngf) and of muteins thereof |
AU2019293579A1 (en) * | 2018-06-29 | 2021-01-07 | The Doshisha | Formulation containing emricasan |
EP3852785A1 (en) | 2018-09-17 | 2021-07-28 | Chiesi Farmaceutici S.p.A. | Agent for treatment of dermatological disorders |
IT201900014646A1 (en) * | 2019-08-12 | 2021-02-12 | Consiglio Nazionale Ricerche | Protease-resistant neurotrophic peptide for the therapeutic treatment of neurodegenerative and / or skin diseases |
MX2022002833A (en) * | 2019-09-17 | 2022-04-06 | Chiesi Farm Spa | Agent for use in treatment or prevention of ophthalmic disorders. |
IL302317A (en) | 2020-10-28 | 2023-06-01 | Dompe Farm Spa | Pharmaceutical packages comprising polypropylene containers and ngf aqueous formulations packaged therein |
EP4039269A1 (en) | 2021-02-05 | 2022-08-10 | Dompe' Farmaceutici S.P.A. | Ngf isoform for use in the treatment of ocular pathologies |
WO2022221351A1 (en) | 2021-04-13 | 2022-10-20 | Dompé Farmaceutici S.P.A. | Treatment of neuropathic corneal pain with ngf |
EP4311554A1 (en) | 2022-07-29 | 2024-01-31 | Dompé farmaceutici S.p.a. | Combination for use in ophthalmology |
EP4316505A1 (en) | 2022-08-05 | 2024-02-07 | Dompé farmaceutici S.p.a. | Intranasal administration of ngf for the treatment of sensorineural hearing loss |
EP4342485A1 (en) | 2022-09-23 | 2024-03-27 | Dompe' Farmaceutici S.P.A. | Ngf for the treatment of spasticity |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4139000A1 (en) * | 1991-11-27 | 1993-06-03 | Boehringer Mannheim Gmbh | METHOD OF GENERATING BIOLOGICALLY ACTIVE SS-NGF |
ATE257514T1 (en) | 1998-10-09 | 2004-01-15 | Scil Proteins Gmbh | METHOD FOR OBTAINING ACTIVE BETA-NGF |
US20030040082A1 (en) | 2001-02-16 | 2003-02-27 | Mark Tuszynski | Mutant pro-neurotrophin with improved activity |
EP1575477B1 (en) | 2001-05-25 | 2012-04-25 | Cornell Research Foundation, Inc. | HIGH AFFINITY LIGAND FOR p75 NEUROTROPHIN RECEPTOR |
DE10360483B4 (en) | 2003-12-22 | 2007-11-15 | Scil Proteins Gmbh | Expression vector and its use |
WO2005068498A2 (en) | 2004-01-19 | 2005-07-28 | Nsgene A/S | Human therapeutic cells secreting nerve growth factor |
US20080050776A1 (en) | 2006-05-26 | 2008-02-28 | Kenneth Neet | Stable mutated pro nerve growth factors |
CN101260398B (en) | 2007-03-07 | 2013-06-05 | 舒泰神(北京)生物制药股份有限公司 | Nerve growth factor gene positioning reconstruction animal and its preparation method and application |
PT2672984E (en) | 2011-12-19 | 2015-10-01 | Wacker Chemie Ag | Novel prongf mutants and uses thereof in the production of beta-ngf |
-
2012
- 2012-12-19 PT PT128056959T patent/PT2672984E/en unknown
- 2012-12-19 EP EP12805695.9A patent/EP2672984B1/en active Active
- 2012-12-19 HU HUE15157320A patent/HUE036265T2/en unknown
- 2012-12-19 AU AU2012357052A patent/AU2012357052B2/en active Active
- 2012-12-19 CN CN201280062855.6A patent/CN104203264B/en active Active
- 2012-12-19 KR KR1020167027254A patent/KR20160120788A/en not_active Application Discontinuation
- 2012-12-19 JP JP2014546588A patent/JP6039146B2/en active Active
- 2012-12-19 DK DK12805695.9T patent/DK2672984T3/en active
- 2012-12-19 ES ES15157320.1T patent/ES2657344T3/en active Active
- 2012-12-19 RS RS20180159A patent/RS56893B1/en unknown
- 2012-12-19 PT PT151573201T patent/PT2907521T/en unknown
- 2012-12-19 MX MX2014007317A patent/MX353074B/en active IP Right Grant
- 2012-12-19 US US14/366,460 patent/US9617322B2/en active Active
- 2012-12-19 SG SG11201402585PA patent/SG11201402585PA/en unknown
- 2012-12-19 TR TR2018/02360T patent/TR201802360T4/en unknown
- 2012-12-19 KR KR1020147019162A patent/KR101837802B1/en active IP Right Grant
- 2012-12-19 SI SI201230289T patent/SI2672984T1/en unknown
- 2012-12-19 CA CA2859262A patent/CA2859262C/en active Active
- 2012-12-19 MX MX2017012894A patent/MX370861B/en unknown
- 2012-12-19 SG SG10201605028VA patent/SG10201605028VA/en unknown
- 2012-12-19 PL PL12805695T patent/PL2672984T3/en unknown
- 2012-12-19 SI SI201231212T patent/SI2907521T1/en unknown
- 2012-12-19 BR BR112014014913-5A patent/BR112014014913B1/en active IP Right Grant
- 2012-12-19 CN CN201711352074.1A patent/CN109400693A/en active Pending
- 2012-12-19 PL PL15157320T patent/PL2907521T3/en unknown
- 2012-12-19 WO PCT/EP2012/076251 patent/WO2013092776A1/en active Application Filing
- 2012-12-19 EA EA201491155A patent/EA031333B1/en unknown
- 2012-12-19 ES ES12805695.9T patent/ES2545701T3/en active Active
- 2012-12-19 DK DK15157320.1T patent/DK2907521T3/en active
- 2012-12-19 RS RS20150561A patent/RS54220B1/en unknown
- 2012-12-19 NO NO15157320A patent/NO2907521T3/no unknown
- 2012-12-19 EP EP15157320.1A patent/EP2907521B1/en active Active
- 2012-12-19 HU HUE12805695A patent/HUE027245T2/en unknown
- 2012-12-19 LT LTEP15157320.1T patent/LT2907521T/en unknown
-
2014
- 2014-05-22 ZA ZA2014/03753A patent/ZA201403753B/en unknown
- 2014-06-15 IL IL233137A patent/IL233137A0/en active IP Right Grant
-
2015
- 2015-03-12 HK HK15102539.7A patent/HK1202055A1/en unknown
- 2015-08-20 SM SM201500201T patent/SMT201500201B/en unknown
- 2015-08-26 CY CY20151100747T patent/CY1117016T1/en unknown
- 2015-08-26 HR HRP20150900TT patent/HRP20150900T1/en unknown
- 2015-12-22 US US14/978,407 patent/US10308694B2/en active Active
-
2016
- 2016-11-03 JP JP2016215749A patent/JP6622683B2/en active Active
-
2018
- 2018-02-21 HR HRP20180307TT patent/HRP20180307T1/en unknown
- 2018-02-21 CY CY20181100195T patent/CY1119926T1/en unknown
- 2018-08-07 JP JP2018148261A patent/JP2019011330A/en active Pending
- 2018-08-08 JP JP2018148957A patent/JP2019006781A/en active Pending
-
2019
- 2019-04-05 US US16/376,969 patent/US20200031893A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200031893A1 (en) | Novel prongf mutants and uses thereof in the production of beta-ngf | |
EP0942930B1 (en) | Purification of neurotrophins | |
US8501439B2 (en) | Method for obtaining active pro-NGF and beta-NGF | |
WO1998021234A9 (en) | Purification of neurotrophins | |
NZ627054B2 (en) | Novel prongf mutants and uses thereof in the production of beta-ngf | |
US20100168386A1 (en) | Fusion protein carrying neurotrophin across the blood-brain barrier, encoding gene and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SCIL PROTEINS GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LOREY, SUSAN;JANOWSKI, BERNHARD;PULTKE, HEIKO;AND OTHERS;SIGNING DATES FROM 20120216 TO 20120321;REEL/FRAME:048839/0454 Owner name: WACKER CHEMIE AG, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SCIL PROTEINS GMBH;REEL/FRAME:048834/0129 Effective date: 20140401 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |